



INDEPENDENT AUDITOR'S REPORT AND AUDITED FINANCIAL STATEMENTS

獨立核數師報告及經審查的財務報表

Independent Auditor's Report	64-67
獨立核數師報告	
Financial Statements	
財務報表	
Consolidated balance sheet	68
綜合資產負債表	
Balance sheet	69
資產負債表	
Consolidated statement of income and expenditure	70
綜合收支結算表	
Consolidated statement of comprehensive income	71
綜合全面收益表	
Consolidated statement of cash flows	72
綜合現金流動報表	
Consolidated statement of changes in net assets	73
綜合淨資產變動報表	
Notes to the financial statements	74-122
財務報表附註	



羅兵咸永道

Independent Auditor's Report To The Members of the Hospital Authority

獨立核數師報告 致醫院管理局成員

Opinion

What we have audited

The consolidated financial statements of the Hospital Authority ("HA") and its subsidiaries (together, the "Group") set out on pages 68 to 122, which comprise:

- the consolidated and HA balance sheets as at 31 March 2017;
- the consolidated statement of income and expenditure for the year then ended;
- the consolidated statement of comprehensive income for the year then ended;
- the consolidated statement of cash flows for the year then ended;
- the consolidated statement of changes in net assets for the year then ended; and
- the notes to the consolidated financial statements, which include a summary of significant accounting policies.

Our opinion

In our opinion, the consolidated financial statements give a true and fair view of the financial position of HA and the consolidated financial position of the Group as at 31 March 2017, and of the Group's consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA").

Basis for Opinion

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code.

意見

我們已審計的內容

醫院管理局(「醫管局」)及其附屬機構(以下統稱「貴集團」)列載於第68至122頁的綜合財務報表，包括：

- 於二零一七年三月三十一日的綜合及醫管局資產負債表；
- 截至該日止年度的綜合收支結算表；
- 截至該日止年度的綜合全面收益表；
- 截至該日止年度的綜合現金流動報表；
- 截至該日止年度的綜合淨資產變動報表；及
- 綜合財務報表附註，包括主要會計政策概要。

我們的意見

我們認為，該等綜合財務報表已根據香港會計師公會頒布的《香港財務報告準則》真實而中肯地反映了於二零一七年三月三十一日醫管局的財務狀況及貴集團的綜合財政狀況，以及貴集團截至該日止年度的綜合財務表現及綜合現金流量。

意見的基礎

我們已根據香港會計師公會頒布的《香港審計準則》進行審計。我們在該等準則下承擔的責任已在本報告「核數師就審計綜合財務報表承擔的責任」部分中作進一步闡述。

我們相信，我們所獲得的審計憑證能充足及適當地為我們的審計意見提供基礎。

獨立性

根據香港會計師公會頒布的《專業會計師道德守則》(以下簡稱「守則」)，我們獨立於貴集團，並已履行守則中的其他專業道德責任。



羅兵咸永道

Independent Auditor's Report To The Members of the Hospital Authority (Continued)

Other Information

HA is responsible for the other information. The other information comprises all of the information included in the annual report other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of HA and Those Charged with Governance for the Consolidated Financial Statements

HA is responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA, and for such internal control as HA determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, HA is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless there are events or conditions that have caused or may cause the Group to cease to continue as a going concern.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

獨立核數師報告

致醫院管理局成員(續)

其他信息

醫管局須對其他信息負責。其他信息包括年報內的所有信息，但不包括綜合財務報表及我們的核數師報告。

我們對綜合財務報表的意見並不涵蓋其他信息，我們亦不對該等其他信息發表任何形式的鑒證結論。

結合我們對綜合財務報表的審計，我們的責任是閱讀其他信息，在此過程中，考慮其他信息是否與綜合財務報表或我們在審計過程中所了解的情況存在重大抵觸或者似乎存在重大錯誤陳述的情況。

基於我們已執行的工作，如果我們認為其他信息存在重大錯誤陳述，我們需要報告該事實。在這方面，我們沒有任何報告。

醫管局及管治層就綜合財務報表須承擔的責任

醫管局須負責根據香港會計師公會頒布的《香港財務報告準則》擬備真實而中肯的綜合財務報表，並對其認為為使綜合財務報表的擬備不存在由於欺詐或錯誤而導致的重大錯誤陳述所需的內部控制負責。

在擬備綜合財務報表時，醫管局負責評估貴集團持續經營的能力，並在適用情況下披露與持續經營有關的事項，以及使用持續經營為會計基礎，除非出現任何事項或情況而導致或可能導致貴集團不能持續經營。

管治層須負責監督貴集團的財務報告過程。



羅兵咸永道

Independent Auditor's Report To The Members of the Hospital Authority (Continued)

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. We report our opinion solely to you, as a body, in accordance with Section 10 of the Hospital Authority Ordinance and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSA's will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSA's, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by HA.

獨立核數師報告

致醫院管理局成員(續)

核數師就審計綜合財務報表 承擔的責任

我們的目標，是對綜合財務報表整體是否不存在由於欺詐或錯誤而導致的重大錯誤陳述取得合理保證，並出具包括我們意見的核數師報告。我們僅按照醫院管理局條例第十條向閣下(作為整體)報告我們的意見，除此之外本報告別無其他目的。我們不會就本報告的內容向任何其他人士負上或承擔任何責任。合理保證是高水平的保證，但不能保證按照《香港審計準則》進行的審計，在某一重大錯誤陳述存在時總能發現。錯誤陳述可以由欺詐或錯誤引起，如果合理預期它們單獨或滙總起來可能影響綜合財務報表使用者依賴綜合財務報表所作出的經濟決定，則有關的錯誤陳述可被視作重大。

在根據《香港審計準則》進行審計的過程中，我們運用了專業判斷，保持了專業懷疑態度。我們亦：

- 識別和評估由於欺詐或錯誤而導致綜合財務報表存在重大錯誤陳述的風險，設計及執行審計程序以應對這些風險，以及獲取充足和適當的審計憑證，作為我們意見的基礎。由於欺詐可能涉及串謀、偽造、蓄意遺漏、虛假陳述，或凌駕於內部控制之上，因此未能發現因欺詐而導致的重大錯誤陳述的風險高於未能發現因錯誤而導致的重大錯誤陳述的風險。
- 了解與審計相關的內部控制，以設計適當的審計程序，但目的並非對貴集團內部控制的有效性發表意見。
- 評價醫管局所採用會計政策的恰當性及作出會計估計和相關披露的合理性。



羅兵咸永道

Independent Auditor's Report To The Members of the Hospital Authority (Continued)

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements (Continued)

- Conclude on the appropriateness of HA's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

PricewaterhouseCoopers
Certified Public Accountants

Hong Kong, 28 September 2017

獨立核數師報告

致醫院管理局成員 (續)

核數師就審計綜合財務報表 承擔的責任 (續)

- 對醫管局採用持續經營會計基礎的恰當性作出結論。根據所獲取的審計憑證，確定是否存在與事項或情況有關的重大不確定性，從而可能導致對貴集團的持續經營能力產生重大疑慮。如果我們認為存在重大不確定性，則有必要在核數師報告中提請使用者注意綜合財務報表中的相關披露。假若有關的披露不足，則我們應當發表非無保留意見。我們的結論是基於核數師報告日止所取得的審計憑證。然而，未來事項或情況可能導致貴集團不能持續經營。
- 評價綜合財務報表的整體列報方式、結構和內容，包括披露，以及綜合財務報表是否中肯反映交易和事項。
- 就貴集團內實體或業務活動的財務信息獲取充足、適當的審計憑證，以便對綜合財務報表發表意見。我們負責貴集團審計的方向、監督和執行。我們為審計意見承擔全部責任。

除其他事項外，我們與管治層溝通了計劃的審計範圍、時間安排、重大審計發現等，包括我們在審計中識別出內部控制的任何重大缺陷。


羅兵咸永道會計師事務所
執業會計師

香港，二零一七年九月二十八日


Consolidated Balance Sheet

綜合資產負債表

	Note 附註	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Non-Current Assets 非流動資產			
Property, plant and equipment 物業、機器及設備	5	5,565,993	5,083,108
Intangible assets 無形資產	6	250,587	233,802
Loans receivable 應收債款	7	1,836	3,020
Placements with the Exchange Fund 外匯基金存款	8	23,300,000	13,300,000
Fixed income instruments 固定入息工具	9	250,000	1,840,000
		29,368,416	20,459,930
Current Assets 流動資產			
Inventories 存貨	10	1,296,482	1,267,360
Loans receivable 應收債款	7	827	947
Accounts receivable 應收賬款	11	326,238	316,406
Other receivables 其他應收賬款	12	297,625	177,123
Deposits and prepayments 按金及預付款項	13	323,605	321,972
Placements with the Exchange Fund 外匯基金存款	8	2,367,339	1,667,266
Fixed income instruments 固定入息工具	9	1,890,000	250,000
Cash and bank balances 現金及銀行結餘	14	17,326,021	29,781,697
		23,828,137	33,782,771
Current Liabilities 流動負債			
Balance with Samaritan Fund 撒瑪利亞基金結餘	15	1,221,289	999,630
Creditors and accrued charges 債權人及應付費用	16	10,488,845	10,108,179
Deposits received 已收按金	17	297,734	241,059
		12,007,868	11,348,868
Net Current Assets 流動資產淨值			
		11,820,269	22,433,903
Total Assets Less Current Liabilities 總資產減流動負債			
		41,188,685	42,893,833
Non-Current Liabilities 非流動負債			
Balance with Samaritan Fund 撒瑪利亞基金結餘	15	6,000,000	6,000,000
Death and disability liabilities 死亡及傷殘福利責任	18	253,418	238,782
Deferred income 遞延收益	19	11,782,280	12,503,367
Public-Private Partnership Endowment Fund 公私營協作留本基金	20	10,000,000	10,000,000
		28,035,698	28,742,149
Net Assets 資產淨值			
		13,152,987	14,151,684
Capital subventions and capital donations 資本補助及資本捐贈	21	5,816,580	5,316,910
Designated fund 指定基金	22	5,077,369	5,077,369
Revenue reserve 收入儲備		2,259,038	3,757,405
Total Funds 基金總額		13,152,987	14,151,684



Dr Kam Pok Man, BBS 甘博文博士
Chairman
Finance Committee
財務委員會主席



Dr Leung Pak Yin, JP 梁栢賢醫生
Chief Executive
行政總裁


The notes on pages 74 to 122 are an integral part of these consolidated financial statements.

第74至122頁的附註是本綜合財務報表的一部分。


Balance Sheet

資產負債表

	Note 附註	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Non-Current Assets 非流動資產			
Property, plant and equipment 物業、機器及設備	5	5,565,993	5,083,108
Intangible assets 無形資產	6	250,587	233,802
Loans receivable 應收債款	7	1,836	3,020
Placements with the Exchange Fund 外匯基金存款	8	23,300,000	13,300,000
Fixed income instruments 固定入息工具	9	250,000	1,840,000
		29,368,416	20,459,930
Current Assets 流動資產			
Inventories 存貨	10	1,296,482	1,267,360
Loans receivable 應收債款	7	827	947
Accounts receivable 應收賬款	11	326,238	316,406
Other receivables 其他應收賬款	12	297,625	177,123
Deposits and prepayments 按金及預付款項	13	323,522	321,889
Placements with the Exchange Fund 外匯基金存款	8	2,367,339	1,667,266
Fixed income instruments 固定入息工具	9	1,890,000	250,000
Cash and bank balances 現金及銀行結餘	14	17,326,021	29,781,697
		23,828,054	33,782,688
Current Liabilities 流動負債			
Balance with Samaritan Fund 撒瑪利亞基金結餘	15	1,221,289	999,630
Creditors and accrued charges 債權人及應付費用	16	10,488,768	10,108,102
Deposits received 已收按金	17	297,734	241,059
		12,007,791	11,348,791
Net Current Assets 流動資產淨值			
		11,820,263	22,433,897
Total Assets Less Current Liabilities 總資產減流動負債			
		41,188,679	42,893,827
Non-Current Liabilities 非流動負債			
Balance with Samaritan Fund 撒瑪利亞基金結餘	15	6,000,000	6,000,000
Death and disability liabilities 死亡及傷殘福利責任	18	253,418	238,782
Deferred income 遞延收益	19	11,782,280	12,503,367
Public-Private Partnership Endowment Fund 公私營協作留本基金	20	10,000,000	10,000,000
		28,035,698	28,742,149
Net Assets 資產淨值			
		13,152,981	14,151,678
Capital subventions and capital donations 資本補助及資本捐贈			
	21	5,816,580	5,316,910
Designated fund 指定基金			
	22	5,077,369	5,077,369
Revenue reserve 收入儲備			
		2,259,032	3,757,399
Total Funds 基金總額			
		13,152,981	14,151,678



Dr Kam Pok Man, BBS 甘博文博士
Chairman
Finance Committee
財務委員會主席



Dr Leung Pak Yin, JP 梁栢賢醫生
Chief Executive
行政總裁

The notes on pages 74 to 122 are an integral part of these financial statements.

第 74 至 122 頁的附註是本財務報表的一部分。

Consolidated Statement of Income and Expenditure 綜合收支結算表

	Note 附註	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
Income 收入			
Recurrent Government subvention 經常性政府補助		52,368,730	50,538,379
Capital Government subvention for building projects 建築工程的資本性政府補助		1,259,367	1,143,406
Hospital/clinic fees and charges 醫院 / 診療所收費	23	3,817,718	3,597,986
Donations 捐贈		40	64
Transfers from 轉調自：			
Designated donation fund 指定捐贈基金	19	171,110	145,645
Minor Works Projects Fund 小型工程項目基金	19	1,103,964	1,066,209
Public-Private Partnership Fund 公私營協作基金	19	181,712	-
Capital subventions 資本補助	21	814,305	1,024,384
Capital donations 資本捐贈	21	161,806	113,686
Investment income 投資收益	24	208,867	188,185
Other income 其他收益		726,912	826,561
		60,814,531	58,644,505
Expenditure 支出			
Staff costs 員工成本	25	(43,083,902)	(40,298,679)
Drugs 藥物		(6,156,112)	(5,710,382)
Medical supplies and equipment 醫療物品及設備		(2,690,534)	(2,558,198)
Utilities charges 公用開支		(1,180,882)	(1,174,165)
Repairs and maintenance 維修及保養		(1,989,457)	(1,894,103)
Building projects funded by the Government 由政府撥款的建築工程	2 (g) (ii) to 至 (iv)	(2,363,331)	(2,209,615)
Operating lease expenses 營運租賃開支		(158,893)	(160,342)
Depreciation and amortisation 折舊及攤銷	5 & 6	(964,804)	(1,108,886)
Other operating expenses 其他營運開支	26	(3,745,175)	(3,379,795)
		(62,333,090)	(58,494,165)
(Deficit)/surplus for the year 年內(虧損) / 盈餘		(1,518,559)	150,340

The notes on pages 74 to 122 are an integral part of these consolidated financial statements.

第74至122頁的附註是本綜合財務報表的一部分。



Consolidated Statement of Comprehensive Income

綜合全面收益表

	Note 附註	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
(Deficit)/surplus for the year 年內(虧損)/盈餘		(1,518,559)	150,340
Other comprehensive income 其他全面收益			
Items that will be reclassified subsequently to income or expenditure: 其後會重新分類為收入或支出的項目：			
– Additions to capital subventions and capital donations 資本補助及資本捐贈增加	21	1,453,623	1,284,623
– Transfers from Minor Works Projects Fund 轉調自小型工程項目基金	21	22,158	17,155
– Transfers to consolidated statement of income and expenditure 轉調往綜合收支結算表	21	(976,111)	(1,138,070)
Item that will not be reclassified to income or expenditure: 不會重新分類為收入或支出的項目：			
– Remeasurement of death liability 死亡福利責任重新計量	18	20,192	21,137
Total comprehensive income for the year 年內全面收益總額		(998,697)	335,185

The notes on pages 74 to 122 are an integral part of these consolidated financial statements.

第74至122頁的附註是本綜合財務報表的一部分。

Consolidated Statement of Cash Flows

綜合現金流動報表

	Note 附註	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
Net cash used in operating activities 營運活動所用現金淨額	29	(2,659,321)	(818,911)
Investing activities 投資活動			
Investment income received 已收投資收益		205,151	227,758
Purchases of property, plant and equipment 購置物業、機器及設備	5	(1,349,462)	(1,182,441)
Purchases of intangible assets 購置無形資產	6	(126,319)	(119,337)
Net decrease / (increase) in bank deposits with original maturity over three months 原來到期日超過三個月的銀行存款的淨額減少 / (增加)		2,551,052	(131,767)
Increase in fixed income instruments 固定入息工具增加		(50,000)	(440,000)
Net cash generated from / (used in) investing activities 投資活動所得 / (所用) 現金淨額		1,230,422	(1,645,787)
Net cash outflow before financing activities 融資前之現金淨額流出		(1,428,899)	(2,464,698)
Financing activities 融資活動			
Interest earned for Minor Works Projects Fund 小型工程項目基金所獲利息		56,159	72,200
Interest earned for Public-Private Partnership Fund 公私營協作基金所獲利息		14,493	-
Capital subventions 資本補助	21	1,265,842	1,187,599
Capital donations 資本捐贈	21	187,781	97,024
Net cash generated from financing activities 融資活動所得之現金淨額		1,524,275	1,356,823
Increase / (decrease) in cash and cash equivalents 現金及現金等值之增加 / (減少)		95,376	(1,107,875)
Cash and cash equivalents at the beginning of the year 年初之現金及現金等值		1,958,325	3,066,200
Cash and cash equivalents at the end of the year 年終之現金及現金等值	14	2,053,701	1,958,325

Notes:

- (1) The interest on the placements with the Exchange Fund on behalf of the Samaritan Fund was netted off with the outstanding balance with the Samaritan Fund and the detailed arrangement is disclosed in note 15.
- (2) The cash flow for HK\$10,000,000,000 bank deposits designated for Public-Private Partnership ("PPP") Endowment Fund was netted off with the HK\$10,000,000,000 placement with the Exchange Fund for the year ended 31 March 2017 and the detailed arrangement is disclosed in note 2(r) and note 20.

註：

- (1) 代撒瑪利亞基金存於外匯基金的存款之利息已經扣除於撒瑪利亞基金的結餘，詳細安排於附註15披露。
- (2) 公私營協作留本基金指定銀行存款之港幣10,000,000,000元現金流量已經扣除截至二零一七年三月三十一日止年度於外匯基金的港幣10,000,000,000元存款，詳細安排於附註2(r)及附註20披露。

The notes on pages 74 to 122 are an integral part of these consolidated financial statements.

第74至122頁的附註是本綜合財務報表的一部分。



Consolidated Statement of Changes in Net Assets

綜合淨資產變動報表

	Capital subventions and capital donations [Note 21] HK\$'000 資本補助 及資本捐贈 [附註21] 港幣千元	Designated Fund HK\$'000 指定基金 港幣千元	Revenue Reserve HK\$'000 收入儲備 港幣千元	Total HK\$'000 總計 港幣千元
At 1 April 2015 於二零一五年四月一日	5,153,202	5,077,369	3,585,928	13,816,499
Total comprehensive income for the year 年內全面收益總額	163,708	-	171,477	335,185
At 31 March 2016 於二零一六年三月三十一日	5,316,910	5,077,369	3,757,405	14,151,684
Total comprehensive income for the year 年內全面收益總額	499,670	-	(1,498,367)	(998,697)
At 31 March 2017 於二零一七年三月三十一日	5,816,580	5,077,369	2,259,038	13,152,987

The notes on pages 74 to 122 are an integral part of these consolidated financial statements.

第74至122頁的附註是本綜合財務報表的一部分。

Notes to the Financial Statements

1. The Hospital Authority

(a) Background

The Hospital Authority ("HA") and its subsidiaries are collectively referred to as the "Group" in the consolidated financial statements. HA is a statutory body established in Hong Kong on 1 December 1990 under the Hospital Authority Ordinance (Cap.113). The Hospital Authority Ordinance provides HA with the powers to manage and control the delivery of public hospital services in Hong Kong. Under the Hospital Authority Ordinance, HA is responsible amongst other matters for the following:

- advising the Government of the Hong Kong Special Administrative Region (the "Government") of the needs of the public for hospital services and of the resources required to meet those needs;
- managing and developing the public hospital system;
- recommending to the Secretary for Food and Health appropriate policies on fees for the use of hospital services by the public;
- establishing public hospitals; and
- promoting, assisting and taking part in education and training of persons involved or to be involved in hospital services or other services relevant to the health of the public, and research relating to hospital services.

Pursuant to Section 5(a) of the Hospital Authority Ordinance, an agreement was entered into between the Government and HA on 3 June 2011 ("Agreement"), under which the Government and HA agreed that HA shall be responsible for managing and controlling the government lands and the hospitals, clinics, facilities, buildings and premises established thereon (as set out in Annex A of the Agreement and referred to as "Properties"), as well as the facilities and amenities (as set out in Annex B of the Agreement) that may be provided on the Properties. The ownership of the Properties continues to be held by the Government.

HA has also entered into agreements with the individual governing bodies of the ex-subservent hospitals which allowed HA to assume ownership of some operating assets as at 1 December 1991 and to manage and control other assets, the ownership of which remains with the individual governing bodies.

As a result, HA has assumed responsibility for the management of the public hospital operations since 1 December 1991. Also, all operating and capital commitments outstanding as at 1 December 1991 were assumed by HA, except for the capital works projects funded under the Capital Works Reserve Fund of the Government.

財務報表附註

1. 醫院管理局

(a) 背景

在綜合財務報表中，醫院管理局（「醫管局」）及其附屬機構統稱為「集團」。醫管局於一九九零年十二月一日根據《醫院管理局條例》（第113章）成立為法定團體。《醫院管理局條例》賦予醫管局管理及掌管香港公立醫院服務的權力。根據《醫院管理局條例》，醫管局的主要工作如下：

- 就公眾對醫院服務之需求及所需之資源，向香港特別行政區政府（「政府」）提供意見；
- 管理及發展公立醫院系統；
- 就公眾使用醫院服務須繳付的費用，向食物及衛生局局長建議恰當的政策；
- 設立公立醫院；及
- 促進、協助及參與為從事或將會從事醫院服務或其他與公共衛生相關服務之人士的教育及培訓，以及有關醫院服務的科研。

根據醫院管理局條例第5(a)條，政府與醫管局在二零一一年六月三日達成協議（「協議」），雙方同意由醫管局管理及掌管有關的政府土地及建於其上的醫院、診療所、設施、建築物及樓宇（按協議附件A所載統稱「物業」），以及物業內的設施和設備（按協議附件B所載），物業的擁有權仍歸政府所有。

醫管局亦與個別前補助醫院的管治機構達成協議，容許醫管局於一九九一年十二月一日接收一些營運資產的擁有權，以及管理和掌管其他擁有權仍屬於個別管治機構的資產。

因此，醫管局由一九九一年十二月一日起全面承擔所有醫院運作的管理。此外，除由政府基本工程儲備基金撥款的基本工程計劃外，對於一九九一年十二月一日仍未完成的所有營運及資本承擔，亦由醫管局負責。

Notes to the Financial Statements

1. The Hospital Authority (Continued)

(a) Background (Continued)

As part of the Government's healthcare reform plan, HA has taken over the management and operation of all general outpatient clinics ("GOPCs") from the Department of Health by July 2003. Under the arrangement, the title and ownership in respect of the related operating assets of the GOPCs were retrospectively transferred to HA in July 2003 after receiving formal approval from the Government in June 2006. These assets were transferred at nil value.

In order to promote the development and research of Chinese medicine in Hong Kong, HA's subsidiary, HACM Limited entered into agreements with 10 non-governmental organisations ("NGOs") in collaboration with certain universities in Hong Kong to operate 18 Chinese Medicine Centres for Training and Research ("CMCTRs"). Under the agreements with the NGOs, HACM Limited has provided an annual subvention to the NGOs for operating CMCTRs in Hong Kong. These NGO clinics have provided Chinese medicine outpatient services including the prescription of Chinese herbal medicine and related services. HACM Limited has also provided funding to six tripartite CMCTRs for provision of Chinese medicine services to HA patients under the Integrated Chinese-Western Medicine ("ICWM") Pilot Programme which have been implemented at seven hospitals for three disease areas.

In order to support the Government-led electronic health record ("eHR") programme, which is an essential part of the healthcare reform, HA has been engaged to serve as the technical agency to the Government, leveraging its experience and know-how in the Clinical Management System ("CMS"). With this role, HA undertakes multiple streams of eHR related projects, which are funded by the recurrent subvention and other designated funding from the Government. During the financial year ended 31 March 2017, HA recognised HK\$279,790,000 (2016: HK\$261,809,000) as other income to match with the expenditure incurred in relation to the eHR related projects.

On 19 October 2011, HA set up a subsidiary, eHR HK Limited, to act as a custodian to hold, maintain and license the intellectual property rights and assets related to the eHR programme.

財務報表附註

1. 醫院管理局 (續)

(a) 背景 (續)

作為政府的醫療改革計劃的一部分，醫管局由二零零三年七月起接管衛生署所有普通科門診診所。根據安排，這些普通科門診診所相關營運資產之業權及擁有權由二零零三年七月起轉讓予醫管局，政府的正式批准於二零零六年六月發出，有關資產以無價值轉讓。

為促進香港中醫藥發展及科研，醫管局及其附屬機構「醫院管理局中醫藥發展有限公司」與十間志願團體簽訂協議，與香港一些大學合作開辦十八間中醫臨床教研中心。根據與志願團體的協議，醫院管理局中醫藥發展有限公司每年提供一筆資助予這些志願團體在香港開辦及營運中醫臨床教研中心。這些診所會提供中醫門診服務，包括處方中藥及相關服務。七間公立醫院就三類病種推行中西醫協作項目先導計劃，醫院管理局中醫藥發展有限公司向六間中醫臨床教研中心提供資助，為參加先導計劃的醫管局病人提供中醫藥服務。

政府推行的電子健康記錄互通系統計劃，是醫療改革一個重要部分。醫管局獲政府委託作為技術代理機構，運用發展臨床管理系統的經驗和專業知識，協助政府推行計劃。作為政府的技術代理機構，醫管局須進行不同範疇的電子健康記錄互通系統相關的計劃，這些計劃由政府的經常性補助及其他指定撥款提供經費。截至二零一七年三月三十一日止之財政年度，醫管局確認港幣279,790,000元(二零一六年：港幣261,809,000元)的款項作為其他收入，以支付電子健康記錄互通系統相關計劃的開支。

於二零一一年十月十九日，醫管局成立 eHR HK Limited 作為其附屬機構，此機構作為保管人，持有、保管及特許有關電子健康記錄互通系統計劃的知識產權及資產。

Notes to the Financial Statements

1. The Hospital Authority (Continued)

(b) Hospitals and other institutions

At 31 March 2017, HA had under its management and control the following hospitals, charitable trusts and institutions:

Hospitals:

Alice Ho Miu Ling Nethersole Hospital
Bradbury Hospice
Caritas Medical Centre
Castle Peak Hospital
Cheshire Home, Chung Hom Kok
Cheshire Home, Shatin
The Duchess of Kent Children's Hospital at Sandy Bay
Grantham Hospital
Haven of Hope Hospital
Hong Kong Buddhist Hospital
Hong Kong Eye Hospital
Kowloon Hospital
Kwai Chung Hospital
Kwong Wah Hospital
MacLehose Medical Rehabilitation Centre
North District Hospital
North Lantau Hospital
Our Lady of Maryknoll Hospital
Pamela Youde Nethersole Eastern Hospital
Pok Oi Hospital
Prince of Wales Hospital
Princess Margaret Hospital
Queen Elizabeth Hospital
Queen Mary Hospital
Ruttonjee Hospital
Shatin Hospital
Siu Lam Hospital
St. John Hospital
Tai Po Hospital
Tang Shiu Kin Hospital
Tin Shui Wai Hospital
Tsan Yuk Hospital
Tseung Kwan O Hospital
Tuen Mun Hospital
Tung Wah Eastern Hospital
Tung Wah Group of Hospitals Fung Yiu King Hospital
Tung Wah Group of Hospitals Wong Tai Sin Hospital
Tung Wah Hospital
United Christian Hospital
Wong Chuk Hang Hospital
Yan Chai Hospital

財務報表附註

1. 醫院管理局 (續)

(b) 醫院及其他機構

在二零一七年三月三十一日，由醫管局管理及掌管的醫院、慈善信託基金及機構如下：

醫院：

雅麗氏何妙齡那打素醫院
白普理寧養中心
明愛醫院
青山醫院
春磡角慈氏護養院
沙田慈氏護養院
大口環根德公爵夫人兒童醫院
葛量洪醫院
靈實醫院
香港佛教醫院
香港眼科醫院
九龍醫院
葵涌醫院
廣華醫院
麥理浩復康院
北區醫院
北大嶼山醫院
聖母醫院
東區尤德夫人那打素醫院
博愛醫院
威爾斯親王醫院
瑪嘉烈醫院
伊利沙伯醫院
瑪麗醫院
律敦治醫院
沙田醫院
小欖醫院
長洲醫院
大埔醫院
鄧肇堅醫院
天水圍醫院
贊育醫院
將軍澳醫院
屯門醫院
東華東院
東華三院馮堯敬醫院
東華三院黃大仙醫院
東華醫院
基督教聯合醫院
黃竹坑醫院
仁濟醫院



Notes to the Financial Statements

財務報表附註

1. The Hospital Authority (Continued)

1. 醫院管理局 (續)

(b) Hospitals and other institutions (Continued)

Charitable Trusts:

North District Hospital Charitable Foundation
 Prince of Wales Hospital Charitable Foundation
 The Hospital Authority Charitable Foundation
 The Hospital Authority New Territories West Cluster Hospitals Charitable Trust
 The Pamela Youde Nethersole Eastern Hospital Charitable Trust
 The Princess Margaret Hospital Charitable Trust
 The Queen Elizabeth Hospital Charitable Trust

Other Institutions:

eHR HK Limited
 HACM Limited
 Hong Kong Red Cross Blood Transfusion Service
 Specialist outpatient clinics
 General outpatient clinics
 Other clinics and associated units

(c) Principal office

The address of the principal office of HA is Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong.

(b) 醫院及其他機構 (續)

慈善信託基金：

北區醫院慈善信託基金
 威爾斯親王醫院慈善信託基金
 醫院管理局慈善基金
 善心醫療基金

東區尤德夫人那打素醫院慈善信託基金
 瑪嘉烈醫院慈善基金
 伊利沙伯醫院慈善信託基金

其他機構：

eHR HK Limited
 醫院管理局中醫藥發展有限公司
 香港紅十字會輸血服務中心
 專科門診診所
 普通科門診診所
 其他診療所及相關科組

(c) 主要辦事處

醫管局的主要辦事處設於香港九龍亞皆老街147號B醫院管理局大樓。

2. Principal accounting policies

The principal accounting policies applied in the preparation of the consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

2. 主要會計政策

編製綜合財務報表所用的主要會計政策列述如下，除非另作說明，這些政策一貫用於呈列所有年度的數字。

(a) Basis of preparation

The financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”) issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”) as appropriate to Government subvented and not-for-profit organisations. They have been prepared under the historical cost convention, as modified by the revaluation of certain financial assets which are stated at fair value.

The financial statements have been prepared on a going concern basis as HA’s ability to continue as a going concern relies primarily on Government funding.

The preparation of financial statements in conformity with HKFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying HA’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 4.

(a) 編製之基準

本財務報表是按照香港會計師公會所發出適用於政府補助及非牟利機構的《香港財務報告準則》，以及根據慣用的原值成本法編製，而某些以公允價值列出的財務資產會經過重新估值而作調整。

由於醫管局的持續經營能力主要是依賴政府撥款，編製財務報表是使用持續經營為會計基礎。

根據《香港財務報告準則》所編製的財務報表，需採用若干關鍵的會計估計，並要求管理層在應用其會計政策的過程中作出判斷。需要較大判斷或較為複雜，或有關假設及估計對財務報表有重要影響的項目，於附註4披露。

Notes to the Financial Statements

財務報表附註

2. Principal accounting policies (Continued)

2. 主要會計政策 (續)

(b) Basis of consolidation

The financial statements of the Group include the income and expenditure of the Head Office, subsidiaries, all Hospitals, Charitable Trusts, Specialist Outpatient Clinics, General Outpatient Clinics and other institutions under its management and control made up to 31 March 2017.

The financial statements reflect the recorded book values of those assets owned and the liabilities assumed by the Group.

(b) 綜合呈列之基準

集團的財務報表包括截至二零一七年三月三十一日之財政年度內由其管理及掌管的總辦事處、附屬機構、所有醫院、慈善信託基金、專科診所、普通科門診診所及其他機構的收入和支出。

本財務報表反映集團所擁有之資產及所承擔之負債的有紀錄賬面值。

(c) Subsidiaries

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date that control is transferred to the Group. They are de-consolidated from the date that control ceases.

Intra-group transactions, balances and unrealised gains on transactions within the Group have been eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the assets transferred. The accounting policies of the subsidiaries are consistent with the accounting policies adopted by the Group.

At 31 March 2017, the principal subsidiaries of HA comprise:

(c) 附屬機構

附屬機構是指集團有管控權的所有實體。當集團能透過其參與實體運作而承擔或享有實體可變回報的風險或權利，並能夠運用其權力指令實體的事務而影響該等回報，即代表集團擁有管控權。在集團接管附屬機構之日，附屬機構與集團的財務資料會作綜合呈列，當集團對附屬機構的管控權終止，便不會作綜合呈列。

集團內機構之間的交易、結餘及未實現之交易收益，在綜合呈列後已減除，未實現之虧損亦已減除，除非交易能提供證明所轉移的資產有耗損。附屬機構的會計政策與集團採用的會計政策一致。

在二零一七年三月三十一日，醫管局的主要附屬機構有：

Name 名稱	Principal activities 主要業務	Place of incorporation/ operation 註冊成立 / 營運地點	Effective percentage directly held by the Group 集團直接持有的 有效份額
HACM Limited (limited by guarantee) 醫院管理局中醫藥發展有限公司 (擔保有限公司)	To steer the development and delivery of Chinese medicine services 規劃中醫藥服務的發展與供應	Hong Kong 香港	100
eHR HK Limited (limited by guarantee) (擔保有限公司)	To act as a custodian to hold, maintain and license the intellectual property rights and assets related to eHR programme 作為保管人，持有、保管及特許有關電子健康記錄互通系統計劃的知識產權及資產	Hong Kong 香港	100



Notes to the Financial Statements

2. Principal accounting policies (Continued)

(d) Adoption of new/revised HKFRSs

The HKICPA has issued a number of new/revised HKFRSs, including interpretations, amendments or improvements to the existing standards, which become effective in the current period. The following amendments to standards which are effective for the Group's financial year beginning 1 April 2016 are relevant to the Group:

Annual Improvements to HKFRS 2012-2014 Cycle

Amendments to HKAS 1, Disclosure Initiative
Amendments to HKAS 16 and 38, Clarification of Acceptable Methods of Depreciation and Amortisation

The adoption of these revised HKFRSs has no significant impact on the results and financial position of the Group.

The HKICPA has also issued a number of new/revised HKFRSs which are effective for accounting period beginning on or after 1 April 2017. The Group has not early adopted these new/revised HKFRSs in the financial statements for the financial year ended 31 March 2017. The Group is in the process of making an assessment but is not yet in a position to conclude the impact of these new/revised HKFRSs on its results of operations and financial position.

(e) Recognition of income

Subventions for recurrent expenditure are recognised on an accruals basis, except for those subventions for designated programmes or capital items that are recognised when the related expenditure is incurred as set out in note 2(r).

Hospital/clinic fees and charges are recognised when services are provided.

Transfers from the designated donation fund and capital donations are recognised as set out in note 2(f).

Transfers from the capital subventions, Minor Works Projects Fund and PPP Fund are recognised as set out in note 2(r).

Investment income from fixed income instruments is recognised as set out in note 2(k).

Investment income from bank deposits is recognised on a time proportion basis using the effective interest method.

財務報表附註

2. 主要會計政策(續)

(d) 採用新訂 / 經修訂的《香港財務報告準則》

香港會計師公會頒布了多項在此期間生效的新訂 / 經修訂的《香港財務報告準則》，包括對現有準則的詮釋、修訂或改良。以下的修訂準則在集團二零一六年四月一日開始之財政年度生效，並適用於集團：

《香港財務報告準則》的年度改進(二零一二年至二零一四年週期)

《香港會計準則》第1號修訂 披露倡議
《香港會計準則》第16及38號修訂 可接受折舊法和攤銷法之澄清

採用這些經修訂的《香港財務報告準則》對集團營運結果及財務狀況並無顯著影響。

香港會計師公會亦頒布了多項在二零一七年四月一日或之後開始的會計期生效之新訂 / 經修訂的《香港財務報告準則》。集團在截至二零一七年三月三十一日止的財務報表並沒有提早採用這些新訂 / 經修訂之《香港財務報告準則》。集團現正作出評估，但現在尚未可總結這些新訂 / 經修訂準則對集團營運結果及財務狀況的影響。

(e) 收入之確認

除非是指定計劃或資本項目的補助按附註2(r)所述在有關開支發生時確認，其他經常性開支之補助會以權責發生制原則確認。

醫院 / 診療所收費於提供服務時確認。

指定用途捐贈基金及資本捐贈之轉調按附註2(f)的方式確認。

資本補助、小型工程項目基金及公私營協作基金之轉調按附註2(r)的方式確認。

來自固定入息工具的投資收益按附註2(k)的方式確認。

來自銀行存款之投資收益採用實際利息法按時間比例入賬。

Notes to the Financial Statements

2. Principal accounting policies (Continued)

(f) Donations

(i) Donated assets

Properties, computer software and systems donated to the Group each with a value below HK\$250,000 and other donated assets each with a value below HK\$100,000 are recorded as income and expenditure in the year of receipt of the assets.

Properties, computer software and systems donated to the Group each with a value of HK\$250,000 or above and other donated assets each with a value of HK\$100,000 or above are capitalised on receipt of assets according to the policy set out in note 2(g)(i) and note 2(i). The amount of the donated assets is recognised in other comprehensive income and accumulated in total funds under capital donations. Each year, an amount equal to the depreciation or amortisation charge for these assets and the net book value of assets disposed of is transferred from capital donations to the statement of income and expenditure.

(ii) Cash donations

Cash donations for specific use as prescribed by the donor are accounted for in the designated donation fund. When the fund is utilised and spent for expenditure not meeting the capitalisation policy as set out in note 2(g)(i) or note 2(i), they are accounted for as expenditure of the designated donation fund. Cash donations that are spent on property, plant and equipment or intangible assets as set out in note 2(g)(v) and note 2(i) respectively are recognised in other comprehensive income and accumulated in total funds under capital donations, and the corresponding amounts are capitalised as property, plant and equipment or intangible assets respectively. Each year, an amount equal to the depreciation or amortisation charge for these assets and the net book value of assets disposed of is transferred from capital donations to the statement of income and expenditure.

Non-designated donations for general operating purposes are recorded as donations in the statement of income and expenditure upon receipt of cash.

財務報表附註

2. 主要會計政策 (續)

(f) 捐贈

(i) 捐贈資產

捐贈予集團而每項價值少於港幣25萬元的物業、電腦軟件及系統，以及其他每項價值少於港幣10萬元的捐贈資產，於收取時在該年度之收支賬目內記賬。

捐贈予集團而每項價值港幣25萬元或以上的物業、電腦軟件及系統，以及其他每項價值港幣10萬元或以上的捐贈資產，按附註2(g)(i)及附註2(i)所列的政策，於收取時資本化。捐贈資產的金額於其他全面收益確認，並在基金總額之下的資本捐贈累積。每年，一筆相等於這些資產折舊或攤銷的金額及出售資產的賬面淨值由資本捐贈轉調往收支結算表。

(ii) 現金捐贈

由捐贈人指定用途的現金捐贈會列入一個指定捐贈基金。當資金的運用及支出不符合附註2(g)(i)或附註2(i)的資本化規定，會列入該指定基金的開支賬目內。當現金捐贈的開支是用於附註2(g)(v)的物業、機器及設備或附註2(i)的無形資產，會於其他全面收益確認，並在基金總額之下的資本捐贈累積，而相同款額亦會資本化為物業、機器及設備或無形資產。每年，一筆相等於這些資產折舊或攤銷的金額及出售資產的賬面淨值由資本捐贈轉調往收支結算表。

作為一般營運之用的非指定用途捐贈，於收款時列入該年度之收支結算表內。



Notes to the Financial Statements

2. Principal accounting policies (Continued)

(g) Capitalisation of property, plant and equipment

- (i) Effective from 1 December 1991, the following categories of assets which give rise to economic benefits have been capitalised:

Building projects costing HK\$250,000 or more; and

All other assets costing HK\$100,000 or more on an individual basis.

The accounting policy for depreciation of property, plant and equipment is set out in note 2(h).

- (ii) For properties which are funded by the Government through HA but are owned by the Government (including those under entrustment arrangement with the Government), the associated expenditure is charged to the statement of income and expenditure in the year as incurred.
- (iii) For properties which are funded by the Government through HA but are owned by an ex-subvented governing body, the associated expenditure is charged to the statement of income and expenditure in the year as incurred. Under the agreements with ex-subvented governing bodies, the ownership of building projects, although funded by the Government through HA, is vested with the governing bodies.
- (iv) For expenditure on subsequent improvement to properties the ownership of which has not been vested with HA, the amount spent is capitalised only if the improvement does not form part of the properties and can be re-used by HA when re-located. Otherwise, the expenditure is charged to the statement of income and expenditure in the year as incurred.
- (v) Expenditure on furniture, fixtures, equipment, motor vehicles and computer hardware is capitalised (subject to the minimum expenditure limits set out in note 2(g)(i) above) and the corresponding amounts are recognised under capital subventions and capital donations for capital expenditure funded by the Government and donations respectively.
- (vi) Property, plant and equipment transferred from the hospitals to HA at 1 December 1991 was recorded at nil value.

財務報表附註

2. 主要會計政策(續)

(g) 物業、機器及設備資本化

- (i) 由一九九一年十二月一日起，下列各類可帶來經濟效益的資產經已資本化：

費用在港幣 25 萬元或以上的建築工程；及

以個別計算，費用在港幣 10 萬元或以上的所有其他資產。

物業、機器及設備的折舊會計政策列於附註 2(h)。

- (ii) 由政府透過醫管局撥款但由政府擁有的財產(包括受政府委托營運管理的財產)，有關開支於支出時記入收支結算表列作開支入賬。
- (iii) 由政府透過醫管局撥款但由前補助機構管治團體擁有的財產，有關開支於支出時記入收支結算表列作開支入賬。根據與前補助機構管治團體的協議，建築工程雖然由政府透過醫管局撥款，但擁有權是屬於有關的管治團體。
- (iv) 至於非由醫管局擁有的物業的隨後改善開支，只要改善不構成物業的一個附連部分及在遷移後可供醫管局重新使用，有關開支應資本化。否則，有關開支會記入開支發生的該年度的收支結算表內。
- (v) 家具、固定裝置、設備、汽車及電腦硬件的開支應資本化(根據上文附註 2(g)(i) 所列的最低限額)。此資本開支，會視乎是政府撥款或捐贈撥款而將相應款額分別在資本補助及資本捐贈確認。
- (vi) 於一九九一年十二月一日由醫院轉調往醫管局的物業、機器及設備以無價值入賬。

Notes to the Financial Statements

財務報表附註

2. Principal accounting policies (Continued)

2. 主要會計政策 (續)

(h) Depreciation

Property, plant and equipment are stated at cost less any accumulated depreciation and impairment. Additions represent new or replacement of specific components of an asset. An asset's carrying value is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

The historical cost of assets acquired and the value of donated assets received by the Group since 1 December 1991 are depreciated using the straight-line method over the expected useful lives of the assets as follows:

Leasehold improvements 租賃物業裝修	Over the life of the lease to which the improvement relates 根據租賃之年期
Buildings 建築物	20 - 50 years 年
Furniture, fixtures and equipment 家具、固定裝置及設備	3 - 10 years 年
Motor vehicles 汽車	5 - 7 years 年
Computer equipment 電腦設備	3 - 6 years 年

The residual values and useful lives of assets are reviewed and adjusted, if appropriate, at each reporting date.

The gain or loss arising from disposal or retirement of an asset is determined as the difference between the proceeds and the carrying amount of the asset and is recognised in the statement of income and expenditure.

Capital expenditure in progress is not depreciated until the asset is placed into commission.

(h) 折舊

物業、機器及設備乃按成本值減任何累積折舊及減值入賬。年內增加代表某項資產新加或更換的組件。若資產的賬面價值高於估計可收回價值，其賬面價值會即時減至為可收回價值。

集團自一九九一年十二月一日起所取得的資產的原值成本或捐贈資產的價值，是按資產的預計可使用年期以直線法計算折舊如下：

如有需要，資產的剩餘價值及可使用年期會在報告日作檢討及修訂。

資產出售或不再使用所產生之盈虧以其出售價及資產之賬面價值之差額計入收支結算表內。

未完成的資本開支在資產啟用前不提折舊。

Notes to the Financial Statements

2. Principal accounting policies (Continued)

(i) Intangible assets

Computer software and systems including related development costs costing HK\$250,000 or more each, which give rise to economic benefits are capitalised as intangible assets. Intangible assets are stated at cost less any accumulated amortisation and impairment and are amortised on a straight line basis over the estimated useful lives of one to three years.

(j) Financial assets at fair value through profit or loss

HA has designated the placements with the Exchange Fund as "financial assets at fair value through profit or loss". HA determines the classification of its financial assets at initial recognition, and such classification depends on the purpose for which the financial assets were acquired. Financial assets carried at fair value through profit or loss are initially recognised at fair value and transaction costs are expensed to the statement of income and expenditure. Financial assets are derecognised when the rights to receive cash flows have expired or have been transferred and HA has transferred substantially all risks and rewards of ownership. Financial assets at fair value through profit or loss are subsequently carried at fair value.

(k) Fixed income instruments

Fixed income instruments are classified as held-to-maturity investments on the basis that the Group has the positive intention and ability to hold the investments to maturity.

Fixed income instruments are recognised on a trade-date basis and stated at amortised cost, less any impairment loss recognised to reflect irrecoverable amounts. The annual amortisation of any discount or premium on the acquisition of fixed income instruments is aggregated with other investment income receivable over the term of the instrument using the effective interest method.

The Group assesses whether there is objective evidence that fixed income instruments are impaired at each reporting date. The amount of the loss is measured as the difference between the carrying amount of the fixed income instruments and the present value of estimated future cash flows, discounted at the original effective interest rate. The carrying amount of the fixed income instruments is reduced and the amount of the loss is recognised in the statement of income and expenditure.

財務報表附註

2. 主要會計政策(續)

(i) 無形資產

費用在港幣 25 萬元或以上可帶來經濟效益的電腦軟件及系統連開發費用，已資本化列為無形資產。無形資產乃按成本值減累積攤銷列出，以及按資產一至三年的預計可使用年期以直線法計算攤銷。

(j) 按公允價值列賬及在損益處理之財務資產

醫管局指定外匯基金存款為「按公允價值列賬及在損益處理之財務資產」。醫管局在最初確認其財務資產時決定其分類，而有關分類視乎獲取該財務資產的目的。按公允價值列賬及在損益處理之財務資產最初以公允價值確認，而交易成本會記入收支結算表。當收取現金流量的權利已到期或已轉讓，並且醫管局已實質上將所有風險和報酬的擁有權轉讓時，便會終止確認該財務資產。按公允價值列賬及在損益處理之財務資產其後按公允價值列賬。

(k) 固定入息工具

固定入息工具歸類為持至到期日的投資，基於集團有意及具能力持有此等投資直至到期日。

固定入息工具是按交易日作為基準予以確認，並以攤餘成本減任何已確認以反映不可收回的金額的減值來計量。而因購買固定入息工具發生的折扣或溢價，則會在該投資工具的期限內，以實際利息法與該項投資的其他應收投資收入合計。

集團於報告日評估有否客觀證據顯示固定入息工具會減值，虧損額是固定入息工具的賬面價值及估計未來現金流量按原來實際息率貼現值的差額。當固定入息工具的賬面價值作出減值，虧損額會在收支結算表確認。

Notes to the Financial Statements

2. Principal accounting policies (Continued)

(l) Inventories

Inventories, which comprise drugs, other medical and general consumable stores, are valued at the lower of cost and net realisable value. Cost is calculated using the weighted average method. Where applicable, provision is made for obsolete and slow-moving items. Inventories are stated net of such provision in the balance sheet. Net realisable value is determined with reference to the replacement cost.

(m) Accounts receivable

Accounts receivable are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for impairment of accounts receivable is established when there is objective evidence that the Group will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will default or delinquency in payments are considered as indicators that the receivable is impaired. The amount of the provision is the difference between the carrying amount of the accounts receivable and the present value of estimated future cash flows, discounted at the original effective interest rate. The carrying amount of the accounts receivable is reduced through the use of an allowance account, and the amount of the loss is recognised as an expense in the statement of income and expenditure. Decrease in the previously recognised impairment loss shall be reversed by adjusting the allowance account. When an accounts receivable is uncollectible and eventually written off, the respective uncollectible amount is offset against the allowance account for accounts receivable. Subsequent recoveries of amounts previously written off are credited against the current year's expenses in the statement of income and expenditure.

(n) Cash and cash equivalents

For the purposes of the statement of cash flows, cash and cash equivalents comprise cash in hand, deposits held at call with banks, and bank deposits with original maturity within three months.

財務報表附註

2. 主要會計政策 (續)

(l) 存貨

存貨包括藥物、其他醫療及一般消耗品，按成本及可變現淨值兩者之較低者入賬。計算成本時使用加權平均方式，有需要時會對過時及消耗緩慢的存貨作撇賬準備。在資產負債表中所列的存貨，是已減去撇賬準備後的款項。可變現淨值乃參考替換成本釐定。

(m) 應收賬款

應收賬款先以公允價值確認，其後以實際利息法，按攤餘成本值減去壞賬撥備後確認。當有客觀證據顯示集團將不能按原來條款收回所有應收賬款，應收賬款便會作出減值撥備。欠款人有重大經濟困難，或欠款人可能拖欠款項或過期不付款，均被視為應收賬款作出減值的跡象。撥備款項是應收賬款的賬面價值及估計未來現金流量按原來實際息率貼現值的差額。應收賬款的賬面價值會利用備抵賬戶減值，虧損額在收支結算表確認為開支。先前確認的壞賬額如減少，會在備抵賬戶作出調整。當應收賬款不能收回並最終註銷，不能收回的款額會在應收賬款的備抵賬戶抵銷，已註銷的款額如日後收回，會記入收支結算表本年度開支的貸方。

(n) 現金及現金等值

在現金流動報表中所列的現金及現金等值，包括手持現金、銀行即期存款，以及原來到期日不超過三個月的現金存款。



Notes to the Financial Statements

財務報表附註

2. Principal accounting policies (Continued)

2. 主要會計政策(續)

(o) Impairment of non-financial assets

Assets that are subject to depreciation and amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use.

(o) 非財務資產減值

需作折舊及攤銷的資產當出現有機會不能收回賬面價值的情況時，便須檢討減值狀況。若資產賬面價值超出可收回價值的數額，會確認為減值虧損。資產的可收回款額，是按資產的公允價值減去出售成本與使用價值的較高者釐定。

(p) Provisions and contingent liabilities

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made.

(p) 撥備及或然負債

當集團因過往事件而致目前負有法律或推定之責任，在履行這項責任時有可能導致資源流出，而涉及金額亦能可靠地作出估量，撥備便會予以確認。

Where it is not probable that an outflow of economic benefits will be required, or the amount cannot be estimated reliably, the obligation is disclosed as a contingent liability, unless the probability of outflow of economic benefits is remote. A contingent liability is a possible obligation that arises from past events and whose existence will only be confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group.

倘經濟效益流出未能肯定，或未能可靠地估量有關金額，則有關責任會以或然負債形式披露，除非經濟效益流出的可能性極低。或然負債是因過往事件引致的可能責任，其存在取決於一項或多項非全由集團控制的未來不肯定事件之發生與否。

Notes to the Financial Statements

2. Principal accounting policies (Continued)

(q) Employee benefits

(i) Retirement benefits costs

Payments to the Group's defined contribution retirement benefit plans are charged as expenses as they fall due. Payments made to the Mandatory Provident Fund Scheme are dealt with as payments to defined contribution plans where the Group's obligations under the schemes are equivalent to those arising in a defined contribution retirement benefit plan. The retirement benefit costs charged in the statement of income and expenditure represent the contributions payable in respect of the current year to the Group's defined contribution retirement benefit plan and the Mandatory Provident Fund Scheme.

(ii) Termination benefits costs

Termination benefits are payable whenever an employee's employment is terminated before the normal retirement age or whenever an employee accepts voluntary redundancy in exchange for these benefits. The Group recognises termination benefits costs when there is an obligation to make such payments without possibility of withdrawal.

(iii) Death and disability benefits costs

The cost of the Group's obligations in respect of death and disability benefits provided to employees is recognised as staff costs in the statement of income and expenditure with reference to annual actuarial valuations performed by an independent qualified actuary.

The death benefits for eligible employees are accounted for as post employment defined benefits. Remeasurement of death liability arising from experience adjustments and changes in actuarial assumptions are recognised immediately in other comprehensive income.

The disability benefits are accounted for as other long-term employee benefits. Remeasurement of disability liability arising from experience adjustments and changes in actuarial assumptions are recognised immediately in the statement of income and expenditure.

Further details of the death and disability liabilities are set out in note 18.

財務報表附註

2. 主要會計政策 (續)

(q) 僱員福利

(i) 退休福利開支

集團付予界定供款退休福利計劃的款項，到期時會以開支入賬。向強制性公積金計劃所作的供款，會作為向界定供款計劃供款處理，集團於這些計劃所負的責任，等同於界定供款退休福利計劃所負的責任。記入收支結算表中的退休福利開支，代表該年度集團向界定供款退休福利計劃及強制性公積金計劃所作的供款。

(ii) 離職福利開支

離職福利是當僱員在正常退休年齡前離職，或接受自願裁減條款以換取這些福利時而須支付的。當集團有責任支付及有關福利不可能撤回，這些離職福利會予以確認。

(iii) 死亡及傷殘福利開支

集團用以支付職員死亡及傷殘福利責任的開支，是根據獨立認可精算師每年所作的精算估值，在收支結算表確認為職員開支。

合資格僱員的死亡福利列為離職後的界定福利。根據經驗調整及精算假設改變而重新計量的死亡福利責任，即時在其他全面收益確認。

傷殘福利列為其他長遠職員福利。根據經驗調整及精算假設改變而重新計量的傷殘福利責任，即時在收支結算表確認。

有關死亡及傷殘福利責任的詳情見附註 18。

Notes to the Financial Statements

2. Principal accounting policies (Continued)

(q) Employee benefits (Continued)

(iv) Other employee benefits costs

Other employee benefits such as annual leave and contract gratuity are accounted for as they accrue.

(r) Government subvention

Subvention grants approved for the year other than the following are classified as recurrent subvention income.

Government grants for building projects are classified and recognised as capital subvention income when the amount is spent on expenditure which does not meet the capitalisation policy of property, plant and equipment as set out in notes 2(g)(i) to (iv).

The one-off grant received from the Government for minor works projects (under Subhead 8083MM) together with the related investment income are recognised as deferred income – Minor Works Projects Fund. Each year, the amount spent on the minor works projects is transferred from deferred income to the statement of income and expenditure or other comprehensive income as appropriate. Further details of the deferred income – Minor Works Projects Fund are set out in note 19(b).

The Government allocated HK\$10,000,000,000 to HA to establish an endowment fund for PPP initiatives. The investment returns of the PPP Endowment Fund, together with the remaining balance of the one-off designated funding for HA's PPP programmes as at 31 March 2016 are recognised as deferred income – PPP Fund. Each year, the amount spent on the PPP programmes is transferred from deferred income to the statement of income and expenditure or other comprehensive income as appropriate. Further details of the PPP Fund are set out in note 19(c).

Government subventions that are spent on property, plant and equipment or intangible assets as set out in note 2(g)(v) and note 2(i) respectively are recognised in other comprehensive income and accumulated in total funds under capital subventions, and the corresponding amounts are capitalised as property, plant and equipment or intangible assets respectively. This includes capital expenditure on furniture, fixtures, equipment, motor vehicles, computer hardware, software and systems. Each year, an amount equal to the depreciation or amortisation charge for these assets and net book value of assets disposed of is transferred from capital subventions to the statement of income and expenditure.

財務報表附註

2. 主要會計政策(續)

(q) 僱員福利(續)

(iv) 其他僱員福利開支

其他僱員福利如年假及約滿酬金於應付時入賬。

(r) 政府補助

除下列外，本年度經核准的政府補助金列為經常性補助金。

建築工程的政府補助，當支出款額不符合附註2(g)(i)至(iv)物業、機器及設備資本化規定時，會列作及確認為資本補助收入。

政府的小型工程一次性撥款(分目8083MM項下)及有關的投資收益確認為遞延收益 – 小型工程項目基金。每年，小型工程項目的支出款額，如適當，由遞延收益轉調往收支結算表或其他全面收益表。遞延收益 – 小型工程項目基金的詳情載於附註19(b)。

政府向醫管局撥款港幣10,000,000,000元設立留本基金，以推行公私營協作計劃。公私營協作留本基金的投資回報，連同政府給予醫管局公私營協作計劃的一次性指定撥款於二零一六年三月三十一日的結餘確認為遞延收益 – 公私營協作基金。每年，公私營協作計劃的支出款額，如適當，由遞延收益轉調往收支結算表或其他全面收益表。有關公私營協作基金的詳情載於附註19(c)。

用於附註2(g)(v)物業、機器及設備或附註2(i)無形資產支出的政府補助，在其他全面收益確認，並在基金總額項下的資本補助累積。相同金額會資本化，分別列為物業、機器及設備或無形資產。這個項目已包括家具、固定裝置、設備、汽車、電腦硬件、軟件及系統。每年，一筆相等於該等資產折舊或攤銷的金額及出售資產的賬面淨值會由資本補助轉調往收支結算表。

Notes to the Financial Statements

2. Principal accounting policies (Continued)

(s) Operating leases

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are recognised as expenses in the statement of income and expenditure on a straight line basis over the period of the lease.

(t) Translation of foreign currencies

Items included in the financial statements of the Group are measured using the currency of the primary economic environment in which the Group operates ("the functional currency"). The financial statements are presented in Hong Kong dollar, which is the Group's functional and presentation currency.

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the reporting date. Exchange gains and losses are dealt with in the statement of income and expenditure except for Minor Works Projects Fund, which are recognised as deferred income.

(u) Related parties

Parties are considered to be related to the Group if the party has the ability, directly or indirectly, to control the Group or exercise significant influence over the Group in making financial and operating decisions, or vice versa. Related parties also include key management personnel having authority and responsibility for planning, directing and controlling the activities of the Group.

For the purpose of these financial statements, transactions between the Group and Government departments, agencies or Government controlled entities, other than those transactions that arise in the normal dealings between the Government and the Group, are considered to be related party transactions.

財務報表附註

2. 主要會計政策(續)

(s) 營運租賃

如有關租賃的大部分風險及擁有權回報歸出租人所有，均分類為營運租賃。根據營運租賃所支付的款項(減去出租人給予的任何優惠)按租賃年期以直線方式於收支結算表確認。

(t) 外幣換算

集團財務報表內各個項目均以集團營運時主要經濟環境的貨幣為計量(「功能貨幣」)。財務報表內呈列的金額以港元為單位，即集團的功能及呈列貨幣。

外幣交易是根據交易日的匯率將外幣轉換為功能貨幣。以外幣為單位的貨幣資產及負債，於資產負債表的日期按匯率轉換，透過轉換所得的盈餘及虧損記入收支結算表，惟小型工程項目基金則除外，會確認為遞延收益。

(u) 關聯人士

與集團關聯的人士，是指直接或間接有能力控制集團作出財政及運作決策，或對此深具影響的關聯人士，反之亦然。關聯人士亦包括具權力及有責任規劃、指令及管控集團事務的主要管理人員。

就本財務報表之編訂，集團與政府部門、機構或政府控制實體之間的交易，除政府與集團的正常交易外，均視作關聯人士交易。

Notes to the Financial Statements

3. Financial risk management

(a) Financial risk factors

The Group's activities of providing healthcare services to patients, the administration of drugs, the employment of a large workforce and the investment activities are primary areas of financial risks being mitigated by the Group's financial risk management process. The Group's underlying principles of financial risk management are to transfer the cost of financial risks of significant level through insurance with a diversity of insurers, to self insure for the operational risks and to comply with regulatory insurance requirements as an employer and owner of a motor fleet.

With regard to investments, in accordance with the Group's policies and guidelines, the primary objectives are to meet liquidity requirements, to protect capital and to provide a reasonable return. The investment portfolio ("Portfolio") as at 31 March 2017 consisted of bank deposits, fixed income instruments and placements with the Exchange Fund. Based on the risk control measures as summarised below, the risk of default by the counterparties is considered minimal and the Portfolio has no significant concentration of credit risk. Besides, the Group has no significant currency risk because substantially all assets and liabilities are denominated in Hong Kong dollar, the Group's functional and presentation currency. The Group manages its cash flow requirements and risk as disclosed in note 3(c).

(i) Credit risk

The Group's credit risk is the risk that counterparties may default on its bank deposits, fixed income instruments and placements with the Exchange Fund.

Bank deposits are placed with the Group's approved banks which are of investment grade as determined by Moody's or Standard and Poor's. For bank deposits, banks must meet the minimum credit rating not lower than Moody's Baa3 or equivalent.

All transactions in fixed income instruments are settled or paid for upon delivery through approved banks and safe kept by the approved custodian with high credit ranking. The credit risks of the issuers are assessed based on the credit rating determined by Moody's or Standard and Poor's. Investments in fixed income instruments (i.e. certificates of deposits) are with issuers of credit rating not lower than Moody's A3 or equivalent. Where the maturity is over three years, the credit rating is not lower than Moody's Aa3 or equivalent at the time of investment.

The placements with the Exchange Fund are entered into between HA and the Hong Kong Monetary Authority ("HKMA") and it is expected that the HKMA can fulfill its contractual obligations to HA in respect of the placements.

財務報表附註

3. 財務風險管理

(a) 財務風險因素

集團所進行的事務如為病人提供醫療服務、管理藥物、僱用龐大職員隊伍及投資活動等，均是主要的財務風險來源，就這些風險進行財務管理可將風險減低。集團財務風險管理的主要原則，是透過向不同保險公司購買保險及自行承保運作風險，將重大風險而導致的財政費用轉移，以及作為僱主及擁有車隊的機構遵守各項保險規管條文。

就投資方面，根據集團有關政策及指引，其主要目標是符合流動資金的需要、保障資金及提供合理回報。截至二零一七年三月三十一日的投資組合（「組合」），包括銀行存款、固定入息工具及外匯基金存款。根據下文所列的風險控制措施，有關銀行的拖欠風險應可減至最低，而組合亦沒有重大的信貸集中風險。此外，由於組合的資產及負債大體上都以港元為單位，即集團的功能及呈列貨幣，故無重大的貨幣風險。集團對流動現金需要及風險的管理，於附註3(c)披露。

(i) 信貸風險

集團的信貸風險是交易對手可能拖欠其銀行存款、固定入息工具及外匯基金存款。

銀行存款均存放於集團的認可銀行，銀行乃根據穆迪或標準普爾釐定的投資評級。就銀行存款而言，銀行的最低信貸評級須不低於穆迪 Baa3 或同等級別。

所有固定入息工具的交易是在交收後透過認可銀行結算/支付，並由具良好信貸評級的認可保管人妥為保管。固定入息工具發行商的信貸風險乃根據穆迪或標準普爾釐定的信貸評級。若投資於固定入息工具（即存款證），有關發行商的最低信貸評級須不低於穆迪 A3 或同等級別。至於到期日超過三年的投資，有關發行商的信貸評級在投資時須不低於穆迪 Aa3 或同等級別。

外匯基金存款是醫管局與香港金融管理局（「金管局」）訂定的安排，預計金管局就這筆存款可履行對醫管局的合約責任。

Notes to the Financial Statements

3. Financial risk management (Continued)

(a) Financial risk factors (Continued)

(ii) Interest rate risk

The Portfolio's interest rate risk arises from interest bearing cash at bank, bank deposits and fixed income instruments. Cash at bank, which earns interest at variable rates, gives rise to cash flow interest rate risk. Fixed rate bank deposits and fixed income instruments expose the Portfolio to fair value interest rate risk. Sensitivity analyses have been performed by the Group with regard to interest rate risk as at 31 March 2017. If interest rates had been increased or decreased by 50 basis points, which represent management's assessment of a reasonably possible change in those rates, and all other variables were held constant, the effect on the Group's deficit and net assets is insignificant.

(iii) Price risk

Fixed income instruments are subject to the price risk caused by the changes in the perceived credit risks of the issuers and market interest rates as disclosed in note 3(a)(i) and note 3(a)(ii) respectively.

(iv) Currency risk

The Group's financial assets and liabilities are substantially denominated in Hong Kong dollar, the Group's functional and presentation currency, and hence will not be exposed to significant currency risk.

(b) Fair values estimation

(i) Financial assets carried at fair values

The Group's financial instruments that are measured at fair value are categorised by level of the following fair value measurement hierarchy:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).

Level 3 – Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).

財務報表附註

3. 財務風險管理 (續)

(a) 財務風險因素 (續)

(ii) 利率風險

組合的利率風險來自所獲利息的銀行現金、銀行存款及固定入息工具。銀行現金賺取不同利率，會有流動現金利率風險；而賺取固定息率的銀行存款及固定入息工具，則有公允價值利率風險。集團在二零一七年三月三十一日就利率風險進行敏感度分析。當利率升降50點子（即管理層認為的合理可能之利率變動），而所有其他變動因素維持不變，這對集團的虧損及資產淨值不會有重大影響。

(iii) 價格風險

因發行商的認知信貸風險（附註3(a)(i)）及市場利率（附註3(a)(ii)）的變動，固定入息工具受價格風險影響。

(iv) 貨幣風險

集團財務資產及負債大體上都以港元為單位，即集團的功能及呈列貨幣，故沒有重大的貨幣風險。

(b) 公允價值估計

(i) 按公允價值列賬的財務資產

集團以公允價值計量的金融工具按以下公允價值的計量架構進行分類：

第一層 – 相同資產或負債於活躍市場之報價（未經調整）。

第二層 – 除了第一層所包括的報價以外，該資產或負債的可觀察的其他輸入，可為直接（即價格）或間接（即源自價格）。

第三層 – 資產或負債並不是根據可觀察市場數據的輸入（即不可觀察輸入）。

Notes to the Financial Statements

3. Financial risk management (Continued)

(b) Fair values estimation (Continued)

(i) Financial assets carried at fair values (Continued)

The fair value of financial instruments traded in active markets is based on quoted market prices at the reporting date. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis. These instruments are included in level 1. None of the instruments of the Group is included in level 1.

The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. None of the instruments of the Group is included in level 2.

If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

Specific valuation techniques used to value financial instruments include:

- Quoted market prices or dealer quotes for similar instruments.
- The fair value of forward foreign exchange contracts is determined using forward exchange rates at the reporting date, with the resulting value discounted back to present value.
- Other techniques, such as discounted cash flow analysis, are used to determine fair value for the remaining financial instruments.

財務報表附註

3. 財務風險管理(續)

(b) 公允價值估計(續)

(i) 按公允價值列賬的財務資產(續)

在活躍市場交易的金融工具的公允價值根據報告日的市場報價列賬。當報價可即時和定期從證券交易市場、交易商、經紀、業內人士、報價服務機構或監管代理獲得，而該等報價代表按公平交易基準進行的真實和常規市場交易，該市場被視為活躍。這些工具屬於第一層。醫管局並無屬於第一層的工具。

沒有在活躍市場交易的金融工具(例如場外衍生工具)的公允價值利用估值技術釐定。估值技術盡量利用可觀察市場數據(如有)，盡量少依賴主體的特定估計。如計算一項金融工具公允價值所需的所有重大輸入為可觀察數據，這些工具屬於第二層。醫管局並無屬於第二層的工具。

如一項或多項重大輸入並非根據可觀察市場數據，這些工具屬於第三層。

用以估值金融工具的特定估值技術包括：

- 同類型工具的市場報價或交易商報價。
- 遠期外匯合約的公允價值使用報告日的遠期匯率釐定，而所得價值折算至現值。
- 其他技術，例如折算現金流分析，用以釐定其餘金融工具的公允價值。

Notes to the Financial Statements

財務報表附註

3. Financial risk management (Continued)

3. 財務風險管理 (續)

(b) Fair values estimation (Continued)

(b) 公允價值估計 (續)

(i) Financial assets carried at fair values (Continued)

The placements with the Exchange Fund are included in level 3. The following table presents the changes in level 3 instruments for the financial years ended 31 March 2017 and 31 March 2016:

	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
At the beginning of the year 於年初	14,967,266	14,262,359
Addition [note 20] 增加[附註20]	10,000,000	-
Interest 利息	700,073	704,907
At the end of the year [note 8] 於年終[附註8]	25,667,339	14,967,266

外匯基金存款屬於第三層。下表呈列截至二零一七年三月三十一日止及二零一六年三月三十一日止年度第三層工具的變動：

(ii) Financial assets not reported at fair values

The fair values of fixed income instruments (i.e. certificates of deposits) at the reporting date are provided by the approved custodian. These instruments are summarised below:

(ii) 非以公允價值呈列的財務資產

固定入息工具(即存款證)在報告日的公允價值由核准保管人提供，現概列如下：

The Group and HA 集團及醫管局

	Carrying Value 賬面價值		Fair Value 公允價值	
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Fixed income instruments 固定入息工具	2,140,000	2,090,000	2,145,364	2,103,181

(iii) The carrying values of other financial assets and liabilities such as cash and bank balances, loans receivable, accounts receivable and trade payables approximate their fair values and accordingly, no disclosure of fair values for these items is presented.

(iii) 其他財務資產及負債如現金及銀行結餘、應收債款、應收賬款及應付貿易賬款的賬面價值與其公允價值相若，故這些項目的公允價值沒有呈列。

Notes to the Financial Statements

3. Financial risk management (Continued)

(c) Capital management

Under the Hospital Authority Ordinance, the resources of the Group consist of the following:

- (i) All money paid by the Government to HA and appropriated for that purpose by the Legislative Council and otherwise provided to HA by the Government; and
- (ii) All other money and property, including gifts, donations, fees, rent, interest and accumulations of income received by HA.

In this regard, the capital of the Group comprises revenue reserve, designated fund, capital subventions, capital donations and deferred income as shown in the consolidated balance sheet. At 31 March 2017, the capital of the Group was HK\$24,935,267,000 (2016: HK\$26,655,051,000).

The Group's objective for managing capital is to safeguard the Group's ability to continue as a going concern to ensure sustainability of the public healthcare system. The Group has always been prudent in financial management so as to ensure proper and effective use of public resources. Through the annual planning exercise, resource requirements of individual hospital clusters are identified and considered against the total amount of funding available to the Group, with a view to meet the rising service demand for public hospital services and build up Hong Kong's future healthcare workforce with recruitment of new graduates. The Group also continuously strives for enhancement of efficiency in use of its resources. To facilitate the delivery of value-for-money services, the Group regularly monitors a set of performance indicators covering performance in clinical service, human resources management and financial management.

財務報表附註

3. 財務風險管理 (續)

(c) 資本管理

根據《醫院管理局條例》，集團的資源包括：

- (i) 由政府付予醫管局及經立法會通過有關撥款用途的所有款項，以及由政府以其他方式撥給醫管局的款項；及
- (ii) 醫管局收到的所有其他款項及財產，包括餽贈、捐贈、費用、租金、利息及累積收入。

故此，集團的資本包括綜合資產負債表所載的收入儲備、指定基金、資本補助、資本捐贈及遞延收益。截至二零一七年三月三十一日，集團的資本為港幣24,935,267,000元（二零一六年：港幣26,655,051,000元）。

集團資本管理的目標是保障集團的能力，繼續在持續經營的基礎上確保公立醫療體制的可持續能力。集團一直奉行審慎的財務管理原則，以確保公共資源獲適當及有效運用。透過年度工作規劃過程，醫管局得悉個別醫院聯網的資源需要，並就集團所獲撥款總額作出考慮，以應付公立醫院服務日益增加的需求，並聘請新畢業生培育香港未來的醫護人手。集團亦不斷致力提升資源運用的效率。為能提供合乎經濟效益的服務，集團定期監察一套測定醫療服務、人力資源管理及財務管理績效的表現指標。

Notes to the Financial Statements

財務報表附註

4. Critical accounting estimates and judgments

In preparing the financial statements, management is required to exercise significant judgments in the selection and application of accounting policies, including making estimates and assumptions. The following is a review of the more significant accounting policies that are impacted by judgments and uncertainties and for which different amounts may be reported under a different set of conditions or using different assumptions.

(a) Provision for medical malpractice claims

The Group co-insures and retains a designated sum for each medical malpractice claim. For those professional liability claims in excess of the retained sum, the claims will be borne by the insurer. In view of the complex nature and long development period of the claims, a Claims Review Panel consisting of the participating medical malpractice insurers, the external panel law firms appointed by the insurers and HA's in-house experts review the status of potential and active claims semi-annually and assess the provision required on each significant case. An independent qualified actuary also assists the Group on the assessment of the exposure of other reported cases based on historical development trend of the claims settlement. With reference to the assessments and the analysis by the Claims Review Panel and the external actuarial consultant respectively, management reviews the claims exposure and determines the provision required to cover the Group's exposure at each reporting date. Such provision is included in accrued charges and other payables in note 16.

(b) Death and disability liabilities

The Group engages an independent qualified actuary to assess the present value of obligations for its death and disability scheme at each year end date. Major actuarial assumptions include the discount rate and salary inflation rate which are set out in note 18. The present value of the Group's obligations is discounted with reference to market yields on Hong Kong Government Bonds, which have terms to maturity approximating the terms of the related obligations. The long-term salary inflation is generally based on the market's long-term expectation of price inflation.

4. 關鍵會計估計及判斷

在制備財務報表時，管理層在會計政策的挑選及應用方面需要運用重大判斷，包括作出估計及假設。以下所列是一些需要運用重大判斷及受不確定因素影響的較重要會計政策，如情況不同，或採用不同的假設，可能會得出不同的呈報數額。

(a) 醫療失誤申索撥備

集團就醫療失誤申索採用共同保險制，並為每項醫療失誤申索預留指定款額。超出預留款額的專業責任申索，會由保險公司承擔。鑑於此等申索的複雜性質及漫長進展，一個由承保醫療失誤責任的保險公司、保險公司所委任的外界律師行小組及醫管局的專家組成的申索檢討委員會，會每半年檢討潛在及現有申索個案的情況，並評估每宗重要個案所需的撥備。合資格獨立精算師亦會根據過往申索補償的發展趨勢，協助集團評估其他呈報個案的申索風險。管理層會參考申索檢討委員會及外界精算顧問分別所作的評估和分析，檢討申索的風險，並於報告日釐定用以應付集團風險的所需撥備，此項撥備列入附註16的「應付費用及其他賬款」。

(b) 死亡及傷殘福利責任

集團委託了合資格的獨立精算師於報告日評估死亡及傷殘計劃福利責任的現值，所採用的主要精算假設包括附註18所述的貼現率及薪金通脹率。集團用以支付此等責任的現值，是根據與有關責任年期相若的香港政府債券的市場回報按貼現率計算，而長遠的薪金通脹率一般是以市場預期的長遠價格通脹率為依據。

Notes to the Financial Statements

財務報表附註

5. Property, plant and equipment

5. 物業、機器及設備

The Group 集團					
	Building and improvements HK\$'000 建築物及裝修 港幣千元	Furniture, fixtures and equipment HK\$'000 家具、固定裝置及設備 港幣千元	Motor vehicles HK\$'000 汽車 港幣千元	Computer equipment HK\$'000 電腦設備 港幣千元	Total HK\$'000 總計 港幣千元
Cost 成本					
At 1 April 2016 於2016年4月1日	1,081,681	10,479,844	253,878	675,911	12,491,314
Reclassifications 重新分類	-	300	-	(338)	(38)
Additions 增加	25,397	1,224,834	32,643	66,588	1,349,462
Disposals 出售	(15,353)	(741,160)	(14,454)	(224,143)	(995,110)
At 31 March 2017 於2017年3月31日	1,091,725	10,963,818	272,067	518,018	12,845,628
Accumulated depreciation 累積折舊					
At 1 April 2016 於2016年4月1日	411,331	6,315,148	197,688	484,039	7,408,206
Reclassifications 重新分類	-	50	-	(88)	(38)
Charge for the year 本年度之折舊	26,336	732,262	27,940	68,732	855,270
Disposals 出售	(13,926)	(735,417)	(14,454)	(220,006)	(983,803)
At 31 March 2017 於2017年3月31日	423,741	6,312,043	211,174	332,677	7,279,635
Net book value 賬面淨值					
At 31 March 2017 於2017年3月31日	667,984	4,651,775	60,893	185,341	5,565,993

HA 醫管局					
	Building and improvements HK\$'000 建築物及裝修 港幣千元	Furniture, fixtures and equipment HK\$'000 家具、固定裝置及設備 港幣千元	Motor vehicles HK\$'000 汽車 港幣千元	Computer equipment HK\$'000 電腦設備 港幣千元	Total HK\$'000 總計 港幣千元
Cost 成本					
At 1 April 2016 於2016年4月1日	1,081,681	10,479,844	253,878	673,274	12,488,677
Reclassifications 重新分類	-	300	-	(338)	(38)
Additions 增加	25,397	1,224,834	32,643	66,588	1,349,462
Disposals 出售	(15,353)	(741,160)	(14,454)	(221,506)	(992,473)
At 31 March 2017 於2017年3月31日	1,091,725	10,963,818	272,067	518,018	12,845,628
Accumulated depreciation 累積折舊					
At 1 April 2016 於2016年4月1日	411,331	6,315,148	197,688	481,402	7,405,569
Reclassifications 重新分類	-	50	-	(88)	(38)
Charge for the year 本年度之折舊	26,336	732,262	27,940	68,732	855,270
Disposals 出售	(13,926)	(735,417)	(14,454)	(217,369)	(981,166)
At 31 March 2017 於2017年3月31日	423,741	6,312,043	211,174	332,677	7,279,635
Net book value 賬面淨值					
At 31 March 2017 於2017年3月31日	667,984	4,651,775	60,893	185,341	5,565,993

Notes to the Financial Statements

財務報表附註

5. Property, plant and equipment (Continued)

5. 物業、機器及設備(續)

The Group 集團

	Building and improvements HK\$'000 建築物及裝修 港幣千元	Furniture, fixtures and equipment HK\$'000 家具、固定裝置及設備 港幣千元	Motor vehicles HK\$'000 汽車 港幣千元	Computer equipment HK\$'000 電腦設備 港幣千元	Total HK\$'000 總計 港幣千元
Cost 成本					
At 1 April 2015 於2015年4月1日	1,064,751	9,802,334	253,687	732,635	11,853,407
Reclassifications 重新分類	39	25,675	-	(35,601)	(9,887)
Additions 增加	16,891	1,080,666	5,771	79,113	1,182,441
Disposals 出售	-	(428,831)	(5,580)	(100,236)	(534,647)
At 31 March 2016 於2016年3月31日	1,081,681	10,479,844	253,878	675,911	12,491,314
Accumulated depreciation 累積折舊					
At 1 April 2015 於2015年4月1日	385,569	6,132,723	176,611	519,966	7,214,869
Reclassifications 重新分類	31	5,383	-	(12,620)	(7,206)
Charge for the year 本年度之折舊	25,731	599,820	26,657	75,938	728,146
Disposals 出售	-	(422,778)	(5,580)	(99,245)	(527,603)
At 31 March 2016 於2016年3月31日	411,331	6,315,148	197,688	484,039	7,408,206
Net book value 賬面淨值					
At 31 March 2016 於2016年3月31日	670,350	4,164,696	56,190	191,872	5,083,108

HA 醫管局

	Building and improvements HK\$'000 建築物及裝修 港幣千元	Furniture, fixtures and equipment HK\$'000 家具、固定裝置及設備 港幣千元	Motor vehicles HK\$'000 汽車 港幣千元	Computer equipment HK\$'000 電腦設備 港幣千元	Total HK\$'000 總計 港幣千元
Cost 成本					
At 1 April 2015 於2015年4月1日	1,064,751	9,802,334	253,687	729,998	11,850,770
Reclassifications 重新分類	39	25,675	-	(35,601)	(9,887)
Additions 增加	16,891	1,080,666	5,771	79,113	1,182,441
Disposals 出售	-	(428,831)	(5,580)	(100,236)	(534,647)
At 31 March 2016 於2016年3月31日	1,081,681	10,479,844	253,878	673,274	12,488,677
Accumulated depreciation 累積折舊					
At 1 April 2015 於2015年4月1日	385,569	6,132,723	176,611	517,329	7,212,232
Reclassifications 重新分類	31	5,383	-	(12,620)	(7,206)
Charge for the year 本年度之折舊	25,731	599,820	26,657	75,938	728,146
Disposals 出售	-	(422,778)	(5,580)	(99,245)	(527,603)
At 31 March 2016 於2016年3月31日	411,331	6,315,148	197,688	481,402	7,405,569
Net book value 賬面淨值					
At 31 March 2016 於2016年3月31日	670,350	4,164,696	56,190	191,872	5,083,108

Notes to the Financial Statements

財務報表附註

6. Intangible assets

6. 無形資產

The Group 集團		
	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
Cost 成本		
At the beginning of the year 於年初	1,268,860	1,164,129
Reclassifications 重新分類	38	9,887
Additions 增加	126,319	119,337
Disposals 出售	(131,781)	(24,493)
At the end of the year 於年終	1,263,436	1,268,860
Accumulated amortisation 累積攤銷		
At the beginning of the year 於年初	1,035,058	649,465
Reclassifications 重新分類	38	7,206
Charge for the year 本年度之攤銷	109,534	380,740
Disposals 出售	(131,781)	(2,353)
At the end of the year 於年終	1,012,849	1,035,058
Net book value 賬面淨值		
At the end of the year 於年終	250,587	233,802

HA 醫管局		
	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
Cost 成本		
At the beginning of the year 於年初	1,258,876	1,154,145
Reclassifications 重新分類	38	9,887
Additions 增加	126,319	119,337
Disposals 出售	(127,720)	(24,493)
At the end of the year 於年終	1,257,513	1,258,876
Accumulated amortisation 累積攤銷		
At the beginning of the year 於年初	1,025,074	641,427
Reclassifications 重新分類	38	7,206
Charge for the year 本年度之攤銷	109,534	378,794
Disposals 出售	(127,720)	(2,353)
At the end of the year 於年終	1,006,926	1,025,074
Net book value 賬面淨值		
At the end of the year 於年終	250,587	233,802

Notes to the Financial Statements

財務報表附註

7. Loans receivable

Certain eligible employees under the Home Loan Interest Subsidy Scheme were offered downpayment loans for the purchase of their residential properties ("Downpayment Loan Scheme"). The repayment period of the loans is the shorter of the mortgage life and 20 years. Interest charged on the downpayment loans is determined by the Group from time to time and is set at 1.282% as at 31 March 2017 (2016: 1.282%). Downpayment Loan Scheme has been suspended since April 2002.

At 31 March 2017, the downpayment loans advanced to eligible staff which are fully secured by charges over the properties are as follows:

The Group and HA 集團及醫管局	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Repayable within one year 一年內償還	827	947
Repayable beyond one year 超過一年償還	1,836	3,020
	2,663	3,967

The loans receivable is neither past due nor impaired. The maximum exposure to credit risk at the reporting date is the carrying value of the receivable mentioned above. According to the terms and conditions of the scheme, the monthly principal repayment and payment of interest in respect of the downpayment loans are deducted from the employees' wages and that any benefits to which an employee will be entitled to receive under the HA Provident Fund Scheme shall stand charged with repayment of downpayment loan and interest thereon if such debt has not been paid by the employee upon resignation or on an agreed date. On this basis, the receivable balance is considered to be fully recoverable.

8. Placements with the Exchange Fund

HA has designated the placements with the Exchange Fund as "financial assets at fair value through profit or loss". The valuation technique and significant unobservable inputs used in the fair value measurements are the discounted cash flow and discount rate respectively. The placements are denominated in Hong Kong dollar. Their fair values are determined with reference to the estimated rates of investment return for future years.

7. 應收債款

在醫管局推行的購屋貸款利息津貼計劃下，一些合資格僱員可獲得首期貸款以購置居所（「首期貸款計劃」）。首期貸款的還款期為物業按揭年數或20年，以較短者為準。首期貸款的息率由醫管局不時訂定，於二零一七年三月三十一日時為1.282%（二零一六年：1.282%）。首期貸款計劃自二零零二年四月起已暫停。

在二零一七年三月三十一日，已發放給合資格僱員的首期貸款並有物業作十足抵押如下：

應收債款並無過期或減值。在報告日最大的信貸風險是上述債款的賬面價值。根據計劃的條款及條件，首期貸款的每月本金及利息還款會在僱員的薪金扣除。若僱員於離職時或議定日期未能償還首期貸款及所涉利息，則僱員根據「醫院管理局公積金計劃」可獲的任何權益，會用作扣減這些欠款。因此，應收債款結餘是可以完全收回。

8. 外匯基金存款

醫管局將存放於外匯基金的款項列為「按公允價值列賬及在損益處理之財務資產」。其公允價值計量所用的估值技術及重大未可觀察輸入，分別是貼現現金流及貼現率。這項款項以港元為單位，其公允價值根據未來年度的估計投資回報率釐定。

Notes to the Financial Statements

財務報表附註

8. Placements with the Exchange Fund (Continued)

The interest on the placements is at a fixed rate determined annually in January and payable annually in arrears on 31 December. Currently, the rate of return is calculated on the basis of the average annual rate of return on certain investment portfolio of the Exchange Fund over the past six years or the average annual yield of three-year government bond in the previous year (subject to a minimum of zero percent), whichever is the higher. This rate of return has been fixed at 3.3% and 2.8% per annum for January to December 2016 and January to December 2017, respectively. HA did not withdraw the interest earned up to 31 December 2016 which would continue to accrue interest at the same rate payable for the principal amount.

The placements with the Exchange Fund are analysed as follows:

8. 外匯基金存款(續)

這筆存款的息率固定，在每年一月釐定，並於每年十二月三十一日支付。現時，回報率是按外匯基金投資組合過往六年的平均投資回報率，或三年期政府債券過去一年的平均年度收益率計算(最低為0%)，以較高者為準。二零一六年一月至十二月及二零一七年一月至十二月的每年回報率分別為3.3%及2.8%。醫管局沒有支取截至二零一六年十二月三十一日賺取的利息，這些款項會按本金可享息率繼續積存利息。

外匯基金存款分析如下：

The Group and HA 集團及醫管局								
	Custodian for Samaritan Fund [Note 15] 作為撒瑪利亞基金的保管人 [附註 15]		Minor Works Projects Fund [Note 19(b)] 小型工程項目基金 [附註 19(b)]		PPP Fund and PPP Endowment Fund [Notes 19(c) and 20] 公私營協作基金及 公私營協作留本基金 [附註 19(c) 及 20]		Total 總計	
	At 31 March 2017 HK\$'000 2017年 3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年 3月31日 港幣千元	At 31 March 2017 HK\$'000 2017年 3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年 3月31日 港幣千元	At 31 March 2017 HK\$'000 2017年 3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年 3月31日 港幣千元	At 31 March 2017 HK\$'000 2017年 3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年 3月31日 港幣千元
Principal amount 本金	6,000,000	6,000,000	7,300,000	7,300,000	10,000,000	-	23,300,000	13,300,000
Interest earned but not withdrawn at the reporting date 報告日所獲但沒有提取的利息收入	1,171,774	942,666	863,586	602,794	155,984	-	2,191,344	1,545,460
Accrued interest 應計利息	49,515	56,964	56,362	64,842	70,118	-	175,995	121,806
	7,221,289	6,999,630	8,219,948	7,967,636	10,226,102	-	25,667,339	14,967,266
Less: non-current portion 減：非流動部分	(6,000,000)	(6,000,000)	(7,300,000)	(7,300,000)	(10,000,000)	-	(23,300,000)	(13,300,000)
Current portion 流動部分	1,221,289	999,630	919,948	667,636	226,102	-	2,367,339	1,667,266

9. Fixed income instruments

The fixed income instruments represent Hong Kong dollar certificates of deposits with maturity periods within five years from the date of purchase. The investment yield for the year ended 31 March 2017 is between 1.47% and 2.55%.

9. 固定入息工具

固定入息工具是指由購買日期起計五年內到期的港元存款證，二零一七年三月三十一日止年度的投資收益在1.47%至2.55%之間。

Notes to the Financial Statements

財務報表附註

9. Fixed income instruments (Continued)

9. 固定入息工具 (續)

At 31 March 2017, the fixed income instruments held by the Group and HA are as follows:

於二零一七年三月三十一日，集團及醫管局持有的固定入息工具如下：

The Group and HA 集團及醫管局		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Maturing within one year 一年內到期	1,890,000	250,000
Maturing between one and five years 一至五年內到期	250,000	1,840,000
	2,140,000	2,090,000

The above financial assets are neither past due nor impaired. The credit quality of these assets is disclosed in note 3(a) while the maximum exposure to credit risk at the reporting date is the fair value of these assets as stated in note 3(b)(ii). The Group does not hold any collateral as security.

上述財務資產並沒有過期或減值，這些資產的信貸質素披露於附註3(a)。在報告日，最大的信貸風險是附註3(b)(ii)所列這些資產的公允價值。集團並未持有任何抵押品作抵押。

10. Inventories

10. 存貨

The Group and HA 集團及醫管局		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Drugs 藥物	1,073,311	1,053,654
Medical consumables 醫療消耗品	195,139	183,227
General consumables 一般消耗品	28,032	30,479
	1,296,482	1,267,360

11. Accounts receivable

11. 應收賬款

The Group and HA 集團及醫管局		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Bills receivable [note 11(a)] 應收賬單 [附註11(a)]	361,952	362,968
Accrued income 應計收入	28,235	11,597
	390,187	374,565
Less: Provision for impairment [note 11(b)] 減：減值撥備 [附註11(b)]	(63,949)	(58,159)
	326,238	316,406

Notes to the Financial Statements

財務報表附註

11. Accounts receivable (Continued)

11. 應收賬款 (續)

(a) Aging analysis of bills receivable is set out below:

(a) 應收賬單的賬齡分析如下：

The Group and HA 集團及醫管局	At 31 March 2017	At 31 March 2016
	HK\$'000	HK\$'000
	2017年3月31日	2016年3月31日
	港幣千元	港幣千元
Below 30 days 30日以下	155,765	151,965
Between 31 and 60 days 31至60日	75,277	98,877
Between 61 and 90 days 61至90日	78,645	48,550
Over 90 days 超過90日	52,265	63,576
	361,952	362,968

The Group's policy in respect of patient billing is as follows:

集團有關病人賬單的政策如下：

- (i) Patients attending outpatient and accident and emergency services are required to pay fees before services are performed.
 - (ii) Private patients and non-eligible persons are required to pay deposit on admission to hospital.
 - (iii) Interim bills are sent to patients during hospitalisation. Final bills are sent if the outstanding amounts have not been settled on discharge.
 - (iv) Administrative charge is imposed on late payments of medical fees and charges for medical services provided on or after 1 July 2007. The administrative charge is imposed at 5% of the outstanding fees past due for 60 days from issuance of the bills, subject to a maximum charge of HK\$1,000 for each bill. An additional 10% of the outstanding fees are imposed if the bills remain outstanding 90 days from issuance of the bills, subject to a maximum additional charge of HK\$10,000 for each bill.
 - (v) Legal action will be instituted for outstanding bills where appropriate. Patients who have financial difficulties may be considered for waiver of fees charged.
- (i) 病人到門診診所及急症室求診須於接受診治前繳付費用。
 - (ii) 私家病人及非符合資格人士入院時須繳付訂金。
 - (iii) 醫院會向住院病人發出中期賬單。假如病人在出院時未繳付尚欠的費用，醫院會發出最後賬單通知。
 - (iv) 就二零零七年七月一日或之後所提供的醫療服務，若過期支付費用須另繳行政費。如在賬單發出後60日仍未清繳費用，會另外徵收欠款5%作為行政費，每項賬單上限為港幣1,000元；如在賬單發出後90日仍未清繳費用，則會另外徵收欠款10%作為行政費，每項賬單上限為港幣10,000元。
 - (v) 集團會就拖欠的賬款按個別情況採取法律行動。有經濟困難的病人，集團會考慮予以費用減免。

Notes to the Financial Statements

財務報表附註

11. Accounts receivable (Continued)

11. 應收賬款 (續)

An aging analysis of receivables that are past due but not impaired is as follows:

過期但沒有減值的應收賬單的賬齡分析如下：

The Group and HA 集團及醫管局		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Past due by 過期：		
Below 30 days 30日以下	123,297	110,812
Between 31 and 60 days 31至60日	59,933	84,285
Between 61 and 90 days 61至90日	67,247	37,998
Over 90 days 超過90日	7,036	18,134
	257,513	251,229

Receivables that are past due but not impaired include outstanding debts to be settled by government departments, charitable organisations or other institutions for whom the credit risk associated with these receivables is relatively low. The Group does not hold any collateral over these balances.

過期但沒有減值的應收賬款包括政府部門、慈善團體或其他機構應償還的欠款，這些應收賬款涉及的信貸風險相對為低，集團並未持有任何抵押品作抵押。

(b) At 31 March 2017, bills receivable of HK\$104,439,000 (2016: HK\$111,739,000) were impaired by HK\$63,949,000 (2016: HK\$58,159,000) of which HK\$39,309,000 (2016: HK\$32,558,000) related to receivables individually determined to be impaired. These mainly related to non-eligible persons, the recoverability of which are considered to be low after taking all possible debt recovery actions. Remaining allowance for impairment of HK\$24,640,000 (2016: HK\$25,601,000) was made by reference to historical past due recovery patterns. It was assessed that a portion of the receivables is expected to be recovered. The aging analysis of these receivables is as follows:

(b) 於二零一七年三月三十一日，港幣104,439,000元(二零一六年：港幣111,739,000元)的應收賬單減值港幣63,949,000元(二零一六年：港幣58,159,000元)，其中港幣39,309,000元(二零一六年：港幣32,558,000元)與個別決定減值的應收賬單有關，主要涉及非符合資格人士，雖然已採取所有可能行動向他們追收欠款，但成功收回機會不大。在參考以往的過期欠款追收情況後，繼而作出了港幣24,640,000元(二零一六年：港幣25,601,000元)餘額減值備抵，估計部分賬款應可收回。這些應收賬單的賬齡分析如下：

The Group and HA 集團及醫管局		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Below 30 days 30日以下	32,468	41,153
Between 31 and 60 days 31至60日	15,344	14,592
Between 61 and 90 days 61至90日	11,398	10,552
Over 90 days 超過90日	45,229	45,442
	104,439	111,739

Notes to the Financial Statements

財務報表附註

11. Accounts receivable (Continued)

11. 應收賬款(續)

Movements in the provision for impairment of accounts receivable are as follows:

應收賬款減值撥備的變動如下：

The Group and HA 集團及醫管局		
	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
At the beginning of the year 於年初	58,159	46,404
Additional provision 撥備增加	60,976	58,126
Uncollectible amounts written off 註銷的未收回款額	(55,186)	(46,371)
At the end of the year 於年終	63,949	58,159

The maximum exposure to credit risk at the reporting date is the fair value of receivable mentioned above. The Group does not hold any collateral as security.

在報告日，最大的信貸風險是上述應收賬款的公允價值，集團並未持有任何抵押品作抵押。

12. Other receivables

12. 其他應收賬款

The Group and HA 集團及醫管局		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Donations receivable 應收捐款	127,509	59,703
Interest receivable 應收利息	71,737	76,334
Receivable from the Government for reimbursement or refund of expenditure incurred on capital projects 政府付還或退還基本工程項目所涉開支的應收款項	57,018	739
Others 其他	41,361	40,347
	297,625	177,123

Other receivables do not contain impaired assets. The maximum exposure to credit risk at the reporting date is the fair value of each class of receivables mentioned above. The Group does not hold any collateral as security.

其他應收款項並無減值資產。在報告日，最大的信貸風險是上述各類應收款項的公允價值，集團並未持有任何抵押品作抵押。

Notes to the Financial Statements

財務報表附註

13. Deposits and prepayments

13. 按金及預付款項

The Group 集團		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Utility and other deposits 公用事業及其他按金	23,145	23,150
Prepayments to Government departments 向政府部門預付的款項	124,969	101,795
Maintenance contracts and other prepayments 保養合約及其他預付款項	175,491	197,027
	323,605	321,972

HA 醫管局		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Utility and other deposits 公用事業及其他按金	23,062	23,067
Prepayments to Government departments 向政府部門預付的款項	124,969	101,795
Maintenance contracts and other prepayments 保養合約及其他預付款項	175,491	197,027
	323,522	321,889



Notes to the Financial Statements

財務報表附註

14. Cash and bank balances

14. 現金及銀行結餘

The Group and HA 集團及醫管局	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Cash at bank and in hand 銀行存款及手持現金	388,222	555,403
Bank deposits with original maturity within three months 原來到期日不超過三個月之銀行存款	1,665,479	1,402,922
Cash and cash equivalents 現金及現金等值	2,053,701	1,958,325
Bank deposits designated for PPP Endowment Fund [note 20] 公私營協作留本基金指定銀行存款 [附註20]	-	10,000,000
Bank deposits with original maturity over three months 原來到期日超過三個月之銀行存款	15,272,320	17,823,372
	17,326,021	29,781,697

The cash and bank balances included bank deposits designated for Minor Works Projects Fund and PPP Fund of HK\$1,639,280,000 (2016: HK\$2,858,121,000) and HK\$299,063,000 (2016: HK\$441,960,000) respectively. The effective interest rate on short term bank deposits is between 0.01% and 1.27% (2016: 0.01% and 0.83%). These deposits have an average maturity of 53 days (2016: 52 days).

現金及銀行結餘包括小型工程項目基金及公私營協作基金的指定銀行存款，分別為港幣1,639,280,000元(二零一六年：港幣2,858,121,000元)及港幣299,063,000元(二零一六年：港幣441,960,000元)。短期銀行存款的實際利率在0.01%至1.27%之間(二零一六年：0.01%至0.83%之間)，這些存款的平均到期日為53天(二零一六年：52天)。

Notes to the Financial Statements

財務報表附註

15. Balance with Samaritan Fund

During the financial year ended 31 March 2013, the Government injected HK\$10,000,000,000 to support the operation of the Samaritan Fund, which was established in 1950 by resolution of the Legislative Council for the purpose of providing financial assistance to needy patients. As instructed by the Government, HK\$4,000,000,000 was vested immediately in the Samaritan Fund. The balance of HK\$6,000,000,000 not immediately required by the Samaritan Fund was placed with the Exchange Fund since 8 November 2012 by way of a credit facility entered into between HA and the Hong Kong Monetary Authority for a fixed period of six years during which time HA would not be able to withdraw the principal amount.

As HA is acting as a custodian for the Samaritan Fund, the cumulative investment return up to 31 March 2017 was recorded together with the principal amount as balance with Samaritan Fund, which is unsecured, interest free and denominated in Hong Kong dollar. The principal amount is repayable upon the maturity of the placement.

The balance with Samaritan Fund is analysed as follows:

15. 撒瑪利亞基金結餘

在截至二零一三年三月三十一日止之財政年度，政府向撒瑪利亞基金注資港幣10,000,000,000元，以支持基金的運作。撒瑪利亞基金於一九五零年經立法局決議成立，目的是向有需要的病人提供資助。根據政府指示，為數港幣4,000,000,000元的款項即時投入基金，而餘下未即時需要的港幣6,000,000,000元，根據醫管局與香港金融管理局所訂的信貸安排，由二零一二年十一月八日起存入外匯基金，年期固定為六年。在此段期間，醫管局不能支取這筆本金。

由於醫管局是作為撒瑪利亞基金的保管人，基金截至二零一七年三月三十一日止年度的累積投資回報連同本金，皆列作撒瑪利亞基金結餘。這筆存款沒抵押及免息，以港元為單位，並於到期日付還。

撒瑪利亞基金結餘分析如下：

The Group and HA 集團及醫管局	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Principal amount 本金	6,000,000	6,000,000
Interest earned but not withdrawn at the reporting date 報告日所獲但沒有提取的利息收入	1,171,774	942,666
Accrued interest 應計利息	49,515	56,964
	7,221,289	6,999,630
Less: non-current portion 減：非流動部分	(6,000,000)	(6,000,000)
Current portion 流動部分	1,221,289	999,630

Notes to the Financial Statements

財務報表附註

16. Creditors and accrued charges

16. 債權人及應付費用

The Group 集團		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Trade payables [note 16(a)] 應付貿易賬款 [附註 16(a)]	604,133	410,460
Accrued charges and other payables [note 16(b)] 應付費用及其他賬款 [附註 16(b)]	5,648,840	5,354,052
Current account with the Government [note 16(c)] 與政府之間的來往賬目 [附註 16(c)]	4,235,872	4,343,667
	10,488,845	10,108,179

HA 醫管局		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Trade payables [note 16(a)] 應付貿易賬款 [附註 16(a)]	604,133	410,460
Accrued charges and other payables [note 16(b)] 應付費用及其他賬款 [附註 16(b)]	5,644,670	5,350,355
Current account with the Government [note 16(c)] 與政府之間的來往賬目 [附註 16(c)]	4,235,872	4,343,667
Current account with a subsidiary 與附屬機構之間的來往賬目	4,093	3,620
	10,488,768	10,108,102

(a) An aging analysis of trade payables is set out below:

(a) 應付貿易賬款的賬齡分析如下：

The Group and HA 集團及醫管局		
	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Below 30 days 30日以下	579,574	351,452
Between 31 and 60 days 31至60日	20,128	42,916
Between 61 and 90 days 61至90日	3,357	9,708
Over 90 days 超過90日	1,074	6,384
	604,133	410,460

All trade payables as at 31 March 2017 are expected to be settled within one year. The Group has maintained adequate cash flows and banking facilities for settlement of trade payables.

二零一七年三月三十一日的應付貿易賬款應於一年內繳付。集團備有足夠流動現金及銀行融資繳付應付貿易賬款。

Notes to the Financial Statements

財務報表附註

16. Creditors and accrued charges (Continued)

- (b) Accrued charges and other payables of the Group and HA included accrual for annual leave of HK\$1,968,565,000 (2016: HK\$1,888,843,000) and contract gratuity accrual of HK\$1,497,136,000 (2016: HK\$1,411,748,000).
- (c) The balance mainly included Government funding for designated programmes or specific items that were already received and will be recognised as income over the periods in which the related expenditure is incurred and charged to the statement of income and expenditure.

16. 債權人及應付費用 (續)

- (b) 集團及醫管局的應付費用及其他賬款包括未放年假撥備港幣 1,968,565,000 元 (二零一六年：港幣 1,888,843,000 元)，以及應計合約酬金港幣 1,497,136,000 元 (二零一六年：港幣 1,411,748,000 元)。
- (c) 結餘主要包括從政府收到對指定計劃或特定項目的撥款，這些撥款待有關開支發生及已記入收支結算表時確認作收入。

17. Deposits received

17. 已收按金

The Group and HA 集團及醫管局	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Patient deposits 病人按金	41,810	42,512
Deposits received from the Government in respect of building projects 就建築工程從政府所收的按金	2,277	44
Other deposits 其他按金	253,647	198,503
	297,734	241,059

18. Death and disability liabilities

Under their terms of employment, HA employees are entitled to death and disability benefit cover. This is funded by HA through the recurrent subvention from the Government.

The amounts recognised in the balance sheet are as follows:

18. 死亡及傷殘福利責任

根據僱用條件，醫管局的僱員可享有死亡及傷殘福利保障。該計劃由醫管局透過政府的經常性補助予以資助。

資產負債表予以確認的款額如下：

The Group and HA 集團及醫管局	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Present value of funded obligations 注資責任的現值	263,757	254,068
Fair value of plan assets 計劃資產的公允價值	(10,339)	(15,286)
	253,418	238,782

Notes to the Financial Statements

財務報表附註

18. Death and disability liabilities (Continued)

18. 死亡及傷殘福利責任(續)

The movement in the present value of funded obligations is as follows:

注資責任之現值變動如下：

The Group and HA 集團及醫管局		
	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
At the beginning of the year 於年初	254,068	239,936
Current service cost 現行服務開支	37,623	33,380
Interest cost 利息開支	3,974	3,757
Benefits paid 已付福利	(8,890)	(5,182)
Remeasurement of disability liability 傷殘福利責任重新計量	(33)	(9,427)
Remeasurement of death liability 死亡福利責任重新計量	(22,985)	(8,396)
At the end of the year 於年終	263,757	254,068

The movement in the fair value of plan assets is as follows:

計劃資產的公允價值變動如下：

The Group and HA 集團及醫管局		
	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
At the beginning of the year 於年初	15,286	2,044
Adjustment on plan assets (excluding interest income) 計劃資產的調整(不包括利息收入)	(2,793)	12,741
Employer contributions 僱主供款	6,736	5,683
Benefits paid 已付福利	(8,890)	(5,182)
At the end of the year 於年終	10,339	15,286

The death benefits are insured by a group life insurance policy and the current insurance policy covers the period up to 31 July 2018. The fair value of plan assets was taken as the present value of the expected death benefits with respect to the obligations covered by the policy.

醫管局透過團體人壽保險為僱員提供死亡福利保障，現行保險計劃有效期至二零一八年七月三十一日。計劃資產的公允價值為保險計劃估計死亡福利責任的現值。

Notes to the Financial Statements

財務報表附註

18. Death and disability liabilities (Continued)

18. 死亡及傷殘福利責任 (續)

The amounts recognised in the consolidated statement of income and expenditure and consolidated statement of comprehensive income have been calculated by reference to an actuarial valuation and are as follows:

下列是在綜合收支結算表及綜合全面收益表予以確認的款額，是根據精算估值得出：

The Group and HA 集團及醫管局	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
Current service cost 現行服務開支	37,623	33,380
Interest cost 利息開支	3,974	3,757
Remeasurement of disability liability 傷殘福利責任重新計量	(33)	(9,427)
Total, included in staff costs [note 25] 總計(包括在員工成本內)[附註25]	41,564	27,710
Remeasurement of death liability 死亡福利責任重新計量	(22,985)	(8,396)
Adjustment on plan assets (excluding interest income) 計劃資產的調整(不包括利息收入)	2,793	(12,741)
Total, included in other comprehensive income 總計(包括在其他全面收益內)	(20,192)	(21,137)

Principal actuarial assumptions used in the actuarial valuation are as follows:

精算估值採用的主要精算假設如下：

The Group and HA 集團及醫管局	For the year ended 31 March 2017 截至2017年 3月31日止年度 %	For the year ended 31 March 2016 截至2016年 3月31日止年度 %
Discount rate 貼現率	1.70	1.60
Assumed rate of future salary increases 假設未來薪金增幅	3.60	3.60

The analysis below shows how the present value of the funded obligations as at 31 March 2017 would have increased / (decreased) as a result of the following changes in the principal actuarial assumptions:

下列分析是根據以下主要精算假設的改變，得出二零一七年三月三十一日注資責任現值的增加 / (減少)：

	Increase in 50 basis points HK\$'000 利率升50點子 港幣千元	Decrease in 50 basis points HK\$'000 利率降50點子 港幣千元
Discount rate 貼現率	(14,878)	16,296
Assumed rate of future salary increases 假設未來薪金增幅	15,666	(14,429)

Notes to the Financial Statements

財務報表附註

19. Deferred income

19. 遞延收益

The Group and HA 集團及醫管局					
	Designated donation fund [Note 2(f)] HK\$'000 指定捐贈 基金 [附註 2(f)] 港幣千元	Tseung Kwan O Hospital Fund [Note 19(a)] HK\$'000 將軍澳醫院 基金 [附註 19(a)] 港幣千元	Minor Works Projects Fund [Note 19(b)] HK\$'000 小型 工程項目 基金 [附註 19(b)] 港幣千元	PPP Fund [Note 19(c)] HK\$'000 公私營 協作基金 [附註 19(c)] 港幣千元	Total HK\$'000 總計 港幣千元
At 1 April 2015 於2015年4月1日	535,050	66,582	12,154,487	-	12,756,119
Additions during the year 年內增加	166,032	-	-	441,960	607,992
Interest earned 所獲利息	-	-	447,373	6	447,379
Exchange loss 匯兌損失	-	-	(12,532)	-	(12,532)
Utilisation during the year 年內應用	-	(8,153)	-	-	(8,153)
Transfers to consolidated statement of comprehensive income 轉調往綜合全面收益表	-	-	(17,155)	-	(17,155)
Transfers to consolidated statement of income and expenditure 轉調往綜合收支結算表	(145,645)	-	(1,066,209)	-	(1,211,854)
Return of unspent funds to the Government 退還給政府的未用款項	-	(58,429)	-	-	(58,429)
At 31 March 2016 於2016年3月31日	555,437	-	11,505,964	441,966	12,503,367
Additions during the year 年內增加	215,347	-	-	1,757	217,104
Interest earned 所獲利息	-	-	299,400	241,975	541,375
Exchange loss 匯兌損失	-	-	(622)	-	(622)
Transfers to consolidated statement of comprehensive income 轉調往綜合全面收益表	-	-	(22,158)	-	(22,158)
Transfers to consolidated statement of income and expenditure 轉調往綜合收支結算表	(171,110)	-	(1,103,964)	(181,712)	(1,456,786)
At 31 March 2017 於2017年3月31日	599,674	-	10,678,620	503,986	11,782,280

(a) Tseung Kwan O Hospital Fund

During the financial year ended 31 March 1996, the Government advanced HK\$2,047,290,000 to HA for the construction of Tseung Kwan O Hospital. All interest earned from this grant is repaid annually to the Government. The hospital was commissioned during the financial year ended 31 March 2000. During the financial year ended 31 March 2016, the project was completed and the unspent funds payable were returned to the Government in June 2016.

(a) 將軍澳醫院基金

於截至一九九六年三月三十一日止的財政年度內，政府預支港幣2,047,290,000元予醫管局，以興建將軍澳醫院。所有來自這筆款項的利息每年歸還政府。將軍澳醫院已於截至二零零零年三月三十一日止的財政年度內啟用。在截至二零一六年三月三十一日止的財政年度，這個項目已經完成，應付的未用款項於二零一六年六月退還給政府。

Notes to the Financial Statements

財務報表附註

19. Deferred income (Continued)

19. 遞延收益 (續)

(b) Minor Works Projects Fund

During the financial year ended 31 March 2014, the Government advanced HK\$13,000,000,000 (under Subhead 8083MM) to HA for minor works projects to improve the existing facilities in public hospitals and clinics. The one-off grant has replaced the annual block funding allocation under Capital Works Reserve Fund - Improvement Works Block Vote (Subhead 8100MX) and covers minor works projects under five planned programmes, with costing not more than HK\$75 million for each individual item. The five programmes are facility rejuvenation programme, capacity enhancement programme, safe engineering programme, universal accessibility programme and regular maintenance/minor works and preparatory works for major capital works projects.

As approved by the Government, HA has placed HK\$7,300,000,000 with the Exchange Fund over a period of six years since 11 April 2014 while the remaining funds have been managed internally and invested within the ambit of HA's prevailing investment guidelines. The approved grant, together with the related investment income, will be fully used to meet the costs of the minor works projects in the coming 10 years or so starting from April 2014. For the use of funds, HA will continue to seek prior approval from the Government for each individual item of expenditure to be funded by the one-off grant, as has been the practice for the use of funds under Subhead 8100MX.

The exchange loss arose from Renminbi (RMB) denominated bank deposits which were switched back to Hong Kong dollar upon maturity in April 2016. The total interest accumulated since the initial investment was sufficient to cover the exchange loss.

Minor Works Projects Fund balance predominantly comprised non-current items.

(c) PPP Fund

The Government allocated to HA a sum of HK\$10,000,000,000 on 31 March 2016 as an endowment fund (note 20) to generate investment returns for regularising and enhancing ongoing clinical PPP programmes, as well as developing new clinical PPP initiatives in future. HA can make use of the investment returns together with the remaining balance of the one-off designated funding provided previously to support the ongoing operation of the PPP programmes commencing from April 2016.

During the financial year ended 31 March 2017, the Government provided recurrent subvention of HK\$1,757,000 to HA for annual pay adjustment of staff deployed on PPP initiatives. The subvention was transferred to the PPP Fund and was recognised in the deferred income – PPP Fund when the subvention was received.

(b) 小型工程項目基金

於截至二零一四年三月三十一日止的財政年度內，政府預支港幣13,000,000,000元(分目8083MM項下)予醫管局，以供進行小型工程項目，改善公立醫院及診所的現時設施。這筆一次性撥款已代替每年透過基本工程儲備基金 — 改善工程的整體撥款(分目8100MX)，並按五個擬定計劃進行每項上限為港幣7,500萬元的小型改善工程。五個計劃包括設施修復計劃、服務量提升計劃、安全機電計劃、加強人人暢道通行計劃，以及定期維修/小型工程及主要工程計劃的預備工作。

醫管局獲政府批准，於二零一四年四月十一日將港幣7,300,000,000元存入外匯基金，為期六年，餘款由內部管理，並根據醫管局現行的投資規定進行投資。獲批撥款連同有關利息收入，將用以支付由二零一四年四月起未來約十年的小型工程項目開支。對於基金的使用，醫管局會沿用過往使用分目8100MX項下基金的做法，就獲一次過撥款資助的每個開支項目事先獲取政府批准。

存放於銀行的人民幣存款在二零一六年四月到期時兌回港幣引致匯兌損失。自投資日起累積的利息總額足以彌補有關匯兌損失。

小型工程項目基金結餘主要包括非流動項目。

(c) 公私營協作基金

於二零一六年三月三十一日，政府向醫管局撥款港幣10,000,000,000元設立留本基金(附註20)，利用所得投資回報以恒常營運和優化持續推行的臨床公私營協作計劃，以及在日後推行新的計劃。醫管局可利用投資回報，連同政府之前給予的一次性指定撥款的結餘，持續營運由二零一六年四月起推行的公私營協作計劃。

於截至二零一七年三月三十一日止的財政年度，政府向醫管局提供港幣1,757,000元經常性補助，用作公私營協作計劃職員的年度薪酬調整。有關補助於收到時轉調往公私營協作基金，並確認為遞延收益 — 公私營協作基金。

Notes to the Financial Statements

財務報表附註

20. Public-Private Partnership Endowment Fund

20. 公私營協作留本基金

As approved by the Government, the endowment fund of HK\$10,000,000,000 has been placed with the Exchange Fund for a period of six years since 12 July 2016.

政府批准醫管局由二零一六年七月十二日起將港幣 10,000,000,000 元的留本基金存於外匯基金，為期六年。

21. Capital subventions and capital donations

21. 資本補助及資本捐贈

The Group 集團			
	Capital subventions [Note 2(r)] HK\$'000 資本補助 [附註 2 (r)] 港幣千元	Capital donations [Note 2(f)] HK\$'000 資本捐贈 [附註 2 (f)] 港幣千元	Total HK\$'000 總計 港幣千元
At 1 April 2015 於 2015 年 4 月 1 日	3,887,198	1,266,004	5,153,202
Additions during the year 年內增加	1,187,599	97,024	1,284,623
Transfers from Minor Works Projects Fund 轉調自小型工程項目基金	17,155	-	17,155
Transfers to consolidated statement of income and expenditure 轉調往綜合收支結算表	(1,024,384)	(113,686)	(1,138,070)
At 31 March 2016 於 2016 年 3 月 31 日	4,067,568	1,249,342	5,316,910
Additions during the year 年內增加	1,265,842	187,781	1,453,623
Transfers from Minor Works Projects Fund 轉調自小型工程項目基金	22,158	-	22,158
Transfers to consolidated statement of income and expenditure 轉調往綜合收支結算表	(814,305)	(161,806)	(976,111)
At 31 March 2017 於 2017 年 3 月 31 日	4,541,263	1,275,317	5,816,580
HA 醫管局			
	Capital subventions [Note 2(r)] HK\$'000 資本補助 [附註 2 (r)] 港幣千元	Capital donations [Note 2(f)] HK\$'000 資本捐贈 [附註 2 (f)] 港幣千元	Total HK\$'000 總計 港幣千元
At 1 April 2015 於 2015 年 4 月 1 日	3,885,252	1,266,004	5,151,256
Additions during the year 年內增加	1,187,599	97,024	1,284,623
Transfers from Minor Works Projects Fund 轉調自小型工程項目基金	17,155	-	17,155
Transfers to statement of income and expenditure 轉調往收支結算表	(1,022,438)	(113,686)	(1,136,124)
At 31 March 2016 於 2016 年 3 月 31 日	4,067,568	1,249,342	5,316,910
Additions during the year 年內增加	1,265,842	187,781	1,453,623
Transfers from Minor Works Projects Fund 轉調自小型工程項目基金	22,158	-	22,158
Transfers to statement of income and expenditure 轉調往收支結算表	(814,305)	(161,806)	(976,111)
At 31 March 2017 於 2017 年 3 月 31 日	4,541,263	1,275,317	5,816,580

Notes to the Financial Statements

22. Designated Fund – Home Loan Interest Subsidy Scheme

The Group offers eligible employees under the scheme an interest subsidy to finance the purchase of a residence in Hong Kong. Eligibility under the scheme is primarily determined by the employee's length of service. The amount of subsidy generally represents half of the interest rate payable by the eligible employee up to a maximum of 6% per annum. However, eligibility and the maximum amount of subsidies granted are subject to a number of restrictions as further defined in the scheme.

The scheme is funded by HA through the recurrent subvention from the Government. A designated fund has been set aside for the scheme and is maintained in designated bank and investment accounts which are included under cash and bank and fixed income instruments balances respectively.

23. Hospital/clinic fees and charges

The charges for hospital services provided by the Group are levied in accordance with those stipulated in the Gazette. Since the Government has established a set of policies and procedures on granting fee waivers to the needy patients, the hospital/clinic fees and charges recognised as income in the consolidated statement of income and expenditure are stated net of such waivers. The amount of hospital/clinics fees and charges waived for the financial year ended 31 March 2017 amounted to HK\$572,515,000 (2016: HK\$548,084,000).

24. Investment income

The investment income for the financial year ended 31 March 2017 included an exchange loss of HK\$2,124,000 (2016: HK\$33,652,000) arising from RMB denominated bank deposits which were switched back to Hong Kong dollar upon maturity in May 2016. The total interest accumulated since the initial investment was sufficient to cover the exchange loss.

財務報表附註

22. 指定基金 – 購屋貸款利息津貼計劃

根據此項計劃，集團為合資格僱員提供一項利息津貼，資助他們在本港購置居所。資格主要決定於僱員的服務年資。津貼金額一般為合資格僱員應付利息率的一半，最高為每年6%。不過，資格及津貼最高限額受到計劃的一些規定所限制。

該計劃由醫管局透過政府的經常性補助予以資助。計劃預留一筆指定基金，用以支付購屋貸款利息津貼福利的有關開支，並存於指定銀行投資戶口，分別列入現金及銀行及固定入息工具結餘內。

23. 醫院 / 診療所收費

集團所提供的醫療服務，是根據憲報所刊載的收費表而收取費用。由於政府已制訂一套給予經濟有困難病人費用減免的政策及程序，故在綜合收支結算表中確認為收入的醫院 / 診療所收費，已扣除了這些減免數額。在截至二零一七年三月三十一日止之財政年度內，獲減免的醫院 / 診療所收費為港幣572,515,000元(二零一六年：港幣548,084,000元)。

24. 投資收益

在截至二零一七年三月三十一日止之財政年度的投資收益，包括在二零一六年五月到期的人民幣銀行存款兌回港幣引致的匯兌損失港幣2,124,000元(二零一六年：港幣33,652,000元)。自投資日起累積的利息總額足以彌補有關匯兌損失。

Notes to the Financial Statements

財務報表附註

25. Staff costs

25. 員工成本

The Group 集團	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
Basic salaries and other short term employee benefits 基本薪金及其他短期僱員福利	39,888,829	37,295,588
Post-employment benefits 離職後福利：		
– Contribution to HA Provident Fund Scheme [note 25(a)] 醫管局公積金計劃供款 [附註25(a)]	2,508,057	2,385,833
– Contribution to Mandatory Provident Fund Scheme [note 25(b)] 強積金計劃供款 [附註25(b)]	645,452	589,548
Death and disability benefits [note 18] 死亡及傷殘福利 [附註18]	41,564	27,710
	43,083,902	40,298,679

(a) HA Provident Fund Scheme (“HAPFS”)

The HAPFS is a defined contribution scheme. The current scheme was established on 1 April 2003 and governed by its Trust Deed and Rules dated 29 January 2003, and registered under section 18 of the Hong Kong Occupational Retirement Schemes Ordinance (“ORSO”).

Most employees who have opted for HA terms of employment are eligible to join the HAPFS on a non-contributory basis. The HAPFS is a defined contribution scheme as all benefits are defined in relation to contributions except that a minimum death benefit equating to twelve months’ salary applies on the death of a member. However, when the member’s account balance is less than his twelve months’ scheme salary, the difference will be contributed by the Death and Disability Scheme of the Group.

The monthly normal contribution by the Group is currently set at 15% of each member’s monthly basic salary. The percentage of benefit entitlement, receivable by the employee on resignation or retirement, increases with the length of service.

At 31 March 2017, the total membership was 29,462 (2016: 29,414). The scheme’s net asset value as at 31 March 2017 was HK\$61,131,801,000 (2016: HK\$55,617,495,000).

(a) 醫院管理局公積金計劃

「醫院管理局公積金計劃」是一項界定供款計劃。現行計劃是根據二零零三年一月二十九日的信託契約與規則，於二零零三年四月一日成立及受其監管，並根據《香港職業退休計劃條例》第十八條註冊。

大部分已選擇醫管局僱用條件的僱員，均有資格參加無需供款的「醫院管理局公積金計劃」。「醫院管理局公積金計劃」是一個界定供款計劃，因為除了於成員去世時發放相等於十二個月薪金的最低死亡福利外，所有利益都視乎供款界定。不過，當成員的賬目結餘較其於該計劃下之十二個月計劃薪金為低，該差額則會由集團的死亡及傷殘基金補足。

集團的每月正常供款現為僱員底薪的15%。僱員在辭職或退休時可獲的利益比率隨服務年資增加。

於二零一七年三月三十一日，計劃共有29,462名成員(二零一六年：29,414名)，計劃的資產淨值為港幣61,131,801,000元(二零一六年：港幣55,617,495,000元)。

Notes to the Financial Statements

25. Staff costs (Continued)

(b) Mandatory Provident Fund Scheme ("MPFS")

In accordance with the Mandatory Provident Fund Schemes Ordinance, the Group set up a MPFS by participating in master trust schemes. HA permanent employees can choose between the HAPFS and the MPFS while contract and temporary employees are required to join the MPFS unless otherwise exempted.

The Group's contributions to MPFS are determined according to each member's terms of employment. Members' mandatory contributions are fixed at 5% of monthly salary up to a maximum of HK\$1,500 per month.

At 31 March 2017, the total membership was 51,307 (2016: 48,730). During the financial year ended 31 March 2017, total members' contributions were HK\$549,122,000 (2016: HK\$499,266,000). The net asset value as at 31 March 2017, including assets transferred from members' previous employment, was HK\$7,130,385,000 (2016: HK\$5,808,324,000).

26. Other operating expenses

Other operating expenses comprise office supplies, hospital supplies, non-capitalised project expenditure and other administrative expenses. For the financial year ended 31 March 2017, other operating expenses included an accrual for auditor's remuneration of HK\$1,950,000 (2016: HK\$2,955,000).

財務報表附註

25. 員工成本 (續)

(b) 強制性公積金計劃

根據《強制性公積金計劃條例》，集團加入集成信託計劃，為職員設立強制性公積金計劃。醫管局常額僱員可選擇參加「醫院管理局公積金計劃」或「強制性公積金計劃」，而合約及臨時僱員須參加「強制性公積金計劃」，除非獲得豁免。

集團對「強制性公積金計劃」的供款，根據每名成員的僱用條件而定。成員的強制性供款固定為月薪5%，以每月港幣1,500元為上限。

於二零一七年三月三十一日，計劃共有51,307名成員(二零一六年：48,730名)。在截至二零一七年三月三十一日止之財政年度內，成員的供款總額為港幣549,122,000元(二零一六年：港幣499,266,000元)。於二零一七年三月三十一日，計劃的資產淨值，包括成員先前職位轉調的資產，為港幣7,130,385,000元(二零一六年：港幣5,808,324,000元)。

26. 其他營運開支

其他營運開支包括辦公室用品、醫院物資、非資本化項目開支及其他行政開支。截至二零一七年三月三十一日止之財政年度，其他營運開支包括應計核數師酬金港幣1,950,000元(二零一六年：港幣2,955,000元)。

Notes to the Financial Statements

財務報表附註

27. Remuneration of Members of the Board and Five Highest Paid Executives

27. 大會成員及五名最高薪行政人員的酬金

- (a) No Board members are remunerated for the services provided in the capacity as Board members.
- (b) The remuneration of the five highest paid executives, which comprises basic salaries and other short term employee benefits and post-employment benefits, and is included in the staff costs for the year, is as follows:

- (a) 所有出任大會成員的人士均沒有因以成員身份提供服務而領取酬金。
- (b) 年內的員工成本已包括支付予以下五名最高薪行政人員的酬金，當中已計入基本薪金及其他短期僱員福利及離職後福利：

Current Position/Name of Executives 現時職位 / 行政人員姓名	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元
Chief Executive 行政總裁 Dr Pak Yin LEUNG 梁栢賢醫生	5,995
Director (Cluster Services) 聯網服務總監 Dr Wai Lun CHEUNG 張偉麟醫生	5,518
Cluster Chief Executive (Hong Kong West) 港島西聯網總監 Dr Che Chung LUK 陸志聰醫生	5,235
Cluster Chief Executive (Kowloon West) 九龍西聯網總監 Dr Sau Ying TUNG 董秀英醫生	5,235
Cluster Chief Executive (Kowloon Central) 九龍中聯網總監 Dr Chi Yuen LO 盧志遠醫生	5,090
	27,073

Note: All executives do not receive any variable remuneration related to performance.

註：所有行政人員並不獲取與表現掛鈎的不定額薪酬。

Current Position/Name of Executives 現時職位 / 行政人員姓名	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
Chief Executive 行政總裁 Dr Pak Yin LEUNG 梁栢賢醫生	5,747
Director (Cluster Services) 聯網服務總監 Dr Wai Lun CHEUNG 張偉麟醫生	5,127
Cluster Chief Executive (Hong Kong West) 港島西聯網總監 Dr Che Chung LUK 陸志聰醫生	4,926
Cluster Chief Executive (Kowloon West) 九龍西聯網總監 Dr Sau Ying TUNG 董秀英醫生	4,926
Cluster Chief Executive (Kowloon Central) 九龍中聯網總監 Dr Chi Yuen LO 盧志遠醫生	4,925
	25,651

Note: All executives do not receive any variable remuneration related to performance.

註：所有行政人員並不獲取與表現掛鈎的不定額薪酬。

Notes to the Financial Statements

財務報表附註

28. Related party transactions

28. 與關聯人士的交易

Significant related party transactions entered into by the Group include the following:

集團與關聯人士所作的重大交易計有：

- (a) HA has entered into agreements with the Electrical and Mechanical Services Department ("EMSD") of the Government for providing biomedical and general electronics engineering services, electrical, mechanical, air-conditioning and building services to the Group. According to the terms of agreements, the amounts incurred for these services for the financial year ended 31 March 2017 amounted to HK\$973,945,000 (2016: HK\$914,422,000). Other services provided by the EMSD for the year (e.g. capital and improvement works) were approximately HK\$550,954,000 (2016: HK\$531,494,000).
- (b) HA has entered into an agreement with the Government to provide serving and retired civil servants, their eligible dependants and other eligible persons with the services and facilities at all public hospitals and clinics free of charge or at the prevailing rates as prescribed in the Civil Service Regulations. For the financial year ended 31 March 2017, revenue foregone in respect of medical services provided to these persons amounted to HK\$364,405,000 (2016: HK\$340,624,000). The cost of such services has been taken into account in the Government's subvention to the Group.
- (c) Remuneration of key management personnel

- (a) 醫管局與政府機電工程署訂立了協議，由該署向集團提供醫學及一般電子工程服務、電力、機械、空調和樓宇服務。根據協議條款，截至二零一七年三月三十一日止之財政年度內有關服務涉及的款額為港幣973,945,000元(二零一六年：港幣914,422,000元)。年內機電工程署提供其他服務(如基本工程及改善工程)的費用約為港幣550,954,000元(二零一六年：港幣531,494,000元)。
- (b) 醫管局與政府訂立了協議，為現職及退休公務員、其合資格的家屬及其他符合資格人士以免費或按公務員條例所訂收費提供公立醫院及診療所的服務及設施。截至二零一七年三月三十一日止之財政年度，為上述人士所提供的醫療服務涉及之免收款項為港幣364,405,000元(二零一六年：港幣340,624,000元)，這些服務的費用已包括在政府給集團的補助內。
- (c) 主要管理人員薪酬

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group. It comprises the Chief Executive, Cluster Chief Executives, Directors and other division heads of the Head Office.

主要管理人員是指具權力及責任規劃、指令及管控集團事務的人士，這包括行政總裁、聯網總監、各總監及總辦事處其他科部主管。

Total remuneration of the key management personnel is shown below:

主要管理人員的薪酬總額如下：

	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
Basic salaries and other short term employee benefits 基本薪金及其他短期僱員福利	64,506	60,679
Post-employment benefits 離職後福利	6,338	6,091
	70,844	66,770

- (d) Other significant related party transactions with the Government include annual recurrent grants, capital subventions (note 21) and designated funds (notes 19 and 22). Details of transactions relating to the Group's retirement schemes are included in note 25.

- (d) 與政府關聯人士進行的其他重大交易包括每年經常性補助、資本補助(附註21)及指定基金(附註19及22)，有關集團退休計劃的交易詳情載於附註25。

Notes to the Financial Statements

財務報表附註

28. Related party transactions (Continued)

- (e) Outstanding balances with the Government as at 31 March 2016 and 2017 are disclosed in notes 8, 12, 13, 15, 16, 17 and 20. The current account with a subsidiary, HACM Limited, is disclosed in note 16.

28. 與關聯人士的交易(續)

- (e) 截至二零一六年及二零一七年三月三十一日與政府之間的未清賬款於附註8,12,13,15,16,17及20披露。與附屬機構「醫院管理局中醫藥發展有限公司」之間的來往賬目於附註16披露。

29. Net cash used in operating activities

29. 營運活動所用現金淨額

The Group 集團	For the year ended 31 March 2017 HK\$'000 截至2017年 3月31日止年度 港幣千元	For the year ended 31 March 2016 HK\$'000 截至2016年 3月31日止年度 港幣千元
(Deficit)/surplus for the year 年內(虧損)/盈餘	(1,518,559)	150,340
Investment income 投資收益	(208,867)	(188,185)
Income transferred from Minor Works Projects Fund 轉調自小型工程項目基金之收入	(1,103,964)	(1,066,209)
Income transferred from PPP Fund 轉調自公私營協作基金之收入	(181,712)	-
Income transferred from capital subventions and capital donations 轉調自資本補助及資本捐贈之收入	(976,111)	(1,138,070)
Loss on disposal of property, plant and equipment and intangible assets 出售物業、機器及設備及無形資產虧損	11,307	29,184
Depreciation and amortisation 折舊及攤銷	964,804	1,108,886
Write-back of provision for doctors' and non-doctors' claims 醫生及非醫生職員補償之撥備撥回	-	(107,695)
Increase in death and disability liabilities 死亡及傷殘福利責任增加	34,828	22,027
Increase in deferred income 遞延收益增加	45,994	12,234
(Increase)/decrease in inventories 存貨(增加)/減少	(29,122)	46,208
Decrease in loans receivable 應收債款減少	1,304	1,279
(Increase)/decrease in accounts receivable 應收賬款(增加)/減少	(9,832)	36,704
(Increase)/decrease in other receivables 其他應收賬款(增加)/減少	(125,099)	33,151
Increase in deposits and prepayments 按金及預付款項增加	(1,633)	(42,342)
Increase in creditors and accrued charges 債權人及應付費用增加	380,666	250,570
Increase in deposits received 已收按金增加	56,675	33,007
Net cash used in operating activities 營運活動所用現金淨額	(2,659,321)	(818,911)

30. Funds held in trust

At 31 March 2017, Health Care and Promotion Scheme of HK\$25,137,000 (2016: HK\$31,713,000) was held in trust for the Government but not included in the financial statements.

30. 信託基金

於二零一七年三月三十一日，集團以信託基金形式為政府管理港幣25,137,000元(二零一六年：港幣31,713,000元)的健康護理及促進計劃，這筆款額未列入財務報表內。

Notes to the Financial Statements

財務報表附註

31. Donations from the Hong Kong Jockey Club Charities Trust

During the financial year ended 31 March 2017, the Hong Kong Jockey Club Charities Trust made donations totalling HK\$100,777,000 (2016: HK\$81,305,000) to the following institutions:

	HK\$'000 港幣千元
Jockey Club Inpatient Facilities Modernisation Scheme (Various hospitals) 賽馬會安寢輕移計劃(不同醫院)	44,510
Kowloon Hospital 九龍醫院	13,354
Wong Tai Sin Hospital 黃大仙醫院	12,204
Queen Elizabeth Hospital 伊利沙伯醫院	10,470
Caritas Medical Centre 明愛醫院	6,250
Enhanced Home Renal Replacement Therapy Programme (Various hospitals) 家居透析計劃(不同醫院)	4,644
United Christian Hospital 基督教聯合醫院	4,402
Princess Margaret Hospital 瑪嘉烈醫院	4,115
Tai Po Hospital 大埔醫院	828
	100,777

The donations were accounted for in the designated donation fund in accordance with the accounting policy set out in note 2(f)(ii).

根據附註2(f)(ii)所載的會計政策，捐贈列入指定捐贈基金內。

32. Commitments

At 31 March 2017, the Group and HA had the following commitments:

(a) Capital commitments

The Group 集團	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Authorised but not contracted for 已獲授權但未訂契約	6,086,787	5,618,968
Contracted for but not provided 已訂契約但未撥備	5,937,837	3,948,641
	12,024,624	9,567,609

32. 承擔

於二零一七年三月三十一日，集團及醫管局有以下之承擔：

(a) 資本承擔

Notes to the Financial Statements

財務報表附註

32. Commitments (Continued)

32. 承擔(續)

(a) Capital commitments (Continued)

(a) 資本承擔(續)

HA 醫管局	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Authorised but not contracted for 已獲授權但未訂契約	6,086,724	5,618,962
Contracted for but not provided 已訂契約但未撥備	5,937,813	3,948,048
	12,024,537	9,567,010

The capital commitments disclosed above include both costs to be capitalised under property, plant and equipment or intangible assets and also costs which are to be charged to the statement of income and expenditure in accordance with the accounting policy set out in note 2(g).

根據附註2(g)所述的會計政策，上述所列的資本承擔包括將會資本化的物業、機器及設備或無形資產費用，以及行將記入收支結算表的開支。

(b) Operating lease commitments

(b) 營運租賃承擔

At 31 March 2017, the Group and HA had commitments for future minimum payments under non-cancellable operating leases which fall due as follows:

於二零一七年三月三十一日，集團及醫管局有各項於下列時間到期的不可撤銷營運租賃之未來最低付款承擔：

The Group and HA 集團及醫管局	At 31 March 2017 HK\$'000 2017年3月31日 港幣千元	At 31 March 2016 HK\$'000 2016年3月31日 港幣千元
Buildings 樓宇		
Within one year 一年內期滿	48,967	45,149
Between one and five years 一至五年內期滿	116,334	144,700
Beyond five years 超過五年期滿	4,600	16,779
	169,901	206,628
Equipment 設備		
Within one year 一年內期滿	51,060	26,451
Between one and five years 一至五年內期滿	81,706	30,026
	132,766	56,477

Notes to the Financial Statements

財務報表附註

33. Taxation

No taxation is provided as HA is exempt from taxation under the Hospital Authority Ordinance.

33. 稅項

醫管局按《醫院管理局條例》獲豁免繳稅，故並無作出稅項準備。

34. Contingent liabilities

Adequate provisions have been made in the financial statements after reviewing the status of outstanding claims and taking into account legal advice received.

34. 或然負債

經評估尚未解決申索個案的狀況，並根據所得法律意見，此財務報表已作出足夠的撥備。

35. Approval of financial statements

The financial statements were approved by members of HA on 28 September 2017.

35. 財務報表的通過

本財務報表已於二零一七年九月二十八日獲醫管局成員通過。